<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2679238-A1" country="EP" doc-number="2679238" kind="A1" date="20140101" family-id="42073900" file-reference-id="287040" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146550448" ucid="EP-2679238-A1"><document-id><country>EP</country><doc-number>2679238</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13181265-A" is-representative="NO"><document-id mxw-id="PAPP154824371" load-source="docdb" format="epo"><country>EP</country><doc-number>13181265</doc-number><kind>A</kind><date>20091002</date><lang>EN</lang></document-id><document-id mxw-id="PAPP168045610" load-source="docdb" format="original"><country>EP</country><doc-number>13181265.3</doc-number><date>20091002</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140451446" ucid="EP-09818550-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>09818550</doc-number><kind>A</kind><date>20091002</date></document-id></priority-claim><priority-claim mxw-id="PPC140446323" ucid="US-10217708-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>10217708</doc-number><kind>P</kind><date>20081002</date></document-id></priority-claim><priority-claim mxw-id="PPC140452021" ucid="US-22221709-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>22221709</doc-number><kind>P</kind><date>20090701</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988138242" load-source="docdb">A61K  38/17        20060101AFI20131127BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988138321" load-source="docdb">A01N  63/00        20060101ALI20131127BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1916228817" load-source="docdb" scheme="CPC">A61K2039/54        20130101 LA20160714BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1916230056" load-source="docdb" scheme="CPC">C12N2310/11        20130101 LA20160714BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1916233050" load-source="docdb" scheme="CPC">A61K2039/577       20130101 LA20160714BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1916234958" load-source="docdb" scheme="CPC">C07K2317/622       20130101 LA20160714BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1916235011" load-source="docdb" scheme="CPC">C07K2317/24        20130101 LA20160714BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1916235088" load-source="docdb" scheme="CPC">A61K  39/001       20130101 LI20160714BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1916236126" load-source="docdb" scheme="CPC">C12N2320/32        20130101 LA20160714BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2091441671" load-source="docdb" scheme="CPC">A61K  39/39558     20130101 FI20150217BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2102479702" load-source="docdb" scheme="CPC">C07K2317/76        20130101 LA20150129BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125071033" load-source="docdb" scheme="CPC">C12N2320/30        20130101 LA20141002BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125071765" load-source="docdb" scheme="CPC">A61K  39/0011      20130101 LI20141002BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125074230" load-source="docdb" scheme="CPC">C12N  15/113       20130101 LI20141002BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125075026" load-source="docdb" scheme="CPC">C07K  16/30        20130101 LI20141007BHEP        </classification-cpc><classification-cpc mxw-id="PCL2125077118" load-source="docdb" scheme="CPC">A61K2039/505       20130101 LA20141002BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132183828" lang="DE" load-source="patent-office">Verfahren zur Modulation der negativen Chemotaxis von Immunzellen</invention-title><invention-title mxw-id="PT132183829" lang="EN" load-source="patent-office">Methods of modulating the negative chemotaxis of immune cells</invention-title><invention-title mxw-id="PT132183830" lang="FR" load-source="patent-office">Méthodes de modulation de la chimotaxie négative de cellules immunitaires</invention-title><citations><patent-citations><patcit mxw-id="PCIT242656743" load-source="docdb" ucid="EP-0120694-B1"><document-id format="epo"><country>EP</country><doc-number>0120694</doc-number><kind>B1</kind><date>19930721</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656742" load-source="docdb" ucid="EP-0125023-B1"><document-id format="epo"><country>EP</country><doc-number>0125023</doc-number><kind>B1</kind><date>19910605</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656744" load-source="docdb" ucid="EP-0194276-B1"><document-id format="epo"><country>EP</country><doc-number>0194276</doc-number><kind>B1</kind><date>19930811</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656745" load-source="docdb" ucid="EP-0239400-B1"><document-id format="epo"><country>EP</country><doc-number>0239400</doc-number><kind>B1</kind><date>19940803</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656746" load-source="docdb" ucid="EP-0451216-B1"><document-id format="epo"><country>EP</country><doc-number>0451216</doc-number><kind>B1</kind><date>19960124</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656747" load-source="docdb" ucid="EP-0519596-A1"><document-id format="epo"><country>EP</country><doc-number>0519596</doc-number><kind>A1</kind><date>19921223</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656758" load-source="docdb" ucid="US-20080213319-A1"><document-id format="epo"><country>US</country><doc-number>20080213319</doc-number><kind>A1</kind><date>20080904</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656748" load-source="docdb" ucid="US-4172124-A"><document-id format="epo"><country>US</country><doc-number>4172124</doc-number><kind>A</kind><date>19791023</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656750" load-source="docdb" ucid="US-4816397-A"><document-id format="epo"><country>US</country><doc-number>4816397</doc-number><kind>A</kind><date>19890328</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656749" load-source="docdb" ucid="US-4816567-A"><document-id format="epo"><country>US</country><doc-number>4816567</doc-number><kind>A</kind><date>19890328</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656751" load-source="docdb" ucid="US-4946778-A"><document-id format="epo"><country>US</country><doc-number>4946778</doc-number><kind>A</kind><date>19900807</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656752" load-source="docdb" ucid="US-5225539-A"><document-id format="epo"><country>US</country><doc-number>5225539</doc-number><kind>A</kind><date>19930706</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656754" load-source="docdb" ucid="US-5545806-A"><document-id format="epo"><country>US</country><doc-number>5545806</doc-number><kind>A</kind><date>19960813</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656753" load-source="docdb" ucid="US-5545807-A"><document-id format="epo"><country>US</country><doc-number>5545807</doc-number><kind>A</kind><date>19960813</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656755" load-source="docdb" ucid="WO-1986001533-A1"><document-id format="epo"><country>WO</country><doc-number>1986001533</doc-number><kind>A1</kind><date>19860313</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656756" load-source="docdb" ucid="WO-2003010539-A1"><document-id format="epo"><country>WO</country><doc-number>2003010539</doc-number><kind>A1</kind><date>20030206</date></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT242656757" load-source="docdb" ucid="WO-2007110755-A1"><document-id format="epo"><country>WO</country><doc-number>2007110755</doc-number><kind>A1</kind><date>20071004</date></document-id><sources><source name="SEA" category="X" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>"Current Protocols In Molecular Biology", vol. 2, 1991, JOHN WILEY &amp; SONS</text><sources><source mxw-id="PNPL53546194" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426</text><sources><source mxw-id="PNPL53546195" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>EUR. J. IMMUNOL., vol. 6, 1976, pages 511 - 519</text><sources><source mxw-id="PNPL53546196" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>FABRIZIO VIANELLO ET AL: "Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 176, no. 5, 1 March 2006 (2006-03-01), pages 2902 - 2914, XP008146900, ISSN: 0022-1767</text><sources><source mxw-id="PNPL53546197" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>HARLOW, E.; D. LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY</text><sources><source mxw-id="PNPL53546198" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258</text><sources><source mxw-id="PNPL53546199" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 2555</text><sources><source mxw-id="PNPL53546200" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497</text><sources><source mxw-id="PNPL53546201" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554</text><sources><source mxw-id="PNPL53546202" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MILSTEIN ET AL., NATURE, vol. 266, 1977, pages 550 - 552</text><sources><source mxw-id="PNPL53546203" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>NEWMAN ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 1455 - 1460</text><sources><source mxw-id="PNPL53546204" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>NOWACKI T M ET AL: "M1655 Apolipoprotein A1 Mimetic 5a-Peptide Inhibits Experimental DSS Colitis By Regulating Monocyte Adhesive Interactions", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 136, no. 5, 1 May 2009 (2009-05-01), pages A - 404, XP026112401, ISSN: 0016-5085, [retrieved on 20090501], DOI: 10.1016/S0016-5085(09)61854-0</text><sources><source mxw-id="PNPL62695298" load-source="docdb" name="SEA" category="AP"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-13181265-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>13181265</doc-number><kind>A</kind><date>20091002</date></document-id></child-doc><parent-doc ucid="EP-09818550.7"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>09818550.7</doc-number><date>20091002</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR918140233" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CELTAXSYS INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR918170314" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CELTAXSYS, INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR918988357" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Celtaxsys, INC.</last-name><iid>101073055</iid><address><street>ATDC Biosciences Center, 0390 311 Ferst Drive</street><city>Atlanta, GA 30332</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918165048" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CHAVAN SURENDRA</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918167527" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CHAVAN, SURENDRA</last-name></addressbook></inventor><inventor mxw-id="PPAR918992395" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>CHAVAN, SURENDRA</last-name><address><street>10302 North Druid Hills Road</street><city>Atlanta, GA 30319</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918134981" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>MOON JONATHAN L</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918135562" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>MOON, JONATHAN L.</last-name></addressbook></inventor><inventor mxw-id="PPAR918990113" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>MOON, JONATHAN L.</last-name><address><street>1713 Parkhill Drive</street><city>Decatur, GA 30032</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918153582" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>BHATT LOPA</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918145869" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>BHATT, LOPA</last-name></addressbook></inventor><inventor mxw-id="PPAR918988027" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>BHATT, LOPA</last-name><address><street>2518 Hemmingway Lane</street><city>Roswell, GA 30075</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918986027" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Chapman, Paul William</last-name><suffix>et al</suffix><iid>100034846</iid><address><street>Kilburn &amp; Strode LLP 20 Red Lion Street</street><city>London WC1R 4PJ</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS548811472" load-source="docdb">AT</country><country mxw-id="DS548910368" load-source="docdb">BE</country><country mxw-id="DS548909076" load-source="docdb">BG</country><country mxw-id="DS548916295" load-source="docdb">CH</country><country mxw-id="DS548857992" load-source="docdb">CY</country><country mxw-id="DS548811473" load-source="docdb">CZ</country><country mxw-id="DS548910369" load-source="docdb">DE</country><country mxw-id="DS548857993" load-source="docdb">DK</country><country mxw-id="DS548857994" load-source="docdb">EE</country><country mxw-id="DS548906958" load-source="docdb">ES</country><country mxw-id="DS548909077" load-source="docdb">FI</country><country mxw-id="DS548909078" load-source="docdb">FR</country><country mxw-id="DS548910374" load-source="docdb">GB</country><country mxw-id="DS548857995" load-source="docdb">GR</country><country mxw-id="DS548910375" load-source="docdb">HR</country><country mxw-id="DS548811474" load-source="docdb">HU</country><country mxw-id="DS548916296" load-source="docdb">IE</country><country mxw-id="DS548910376" load-source="docdb">IS</country><country mxw-id="DS548909079" load-source="docdb">IT</country><country mxw-id="DS548857996" load-source="docdb">LI</country><country mxw-id="DS548829654" load-source="docdb">LT</country><country mxw-id="DS548811475" load-source="docdb">LU</country><country mxw-id="DS548829655" load-source="docdb">LV</country><country mxw-id="DS548829656" load-source="docdb">MC</country><country mxw-id="DS548894038" load-source="docdb">MK</country><country mxw-id="DS548894039" load-source="docdb">MT</country><country mxw-id="DS548910377" load-source="docdb">NL</country><country mxw-id="DS548909080" load-source="docdb">NO</country><country mxw-id="DS548829657" load-source="docdb">PL</country><country mxw-id="DS548916297" load-source="docdb">PT</country><country mxw-id="DS548910382" load-source="docdb">RO</country><country mxw-id="DS548829658" load-source="docdb">SE</country><country mxw-id="DS548916298" load-source="docdb">SI</country><country mxw-id="DS548909081" load-source="docdb">SK</country><country mxw-id="DS548829659" load-source="docdb">SM</country><country mxw-id="DS548857997" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128671115" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
<img id="iaf01" file="imgaf001.tif" wi="133" he="97" img-content="drawing" img-format="tif"/></p></abstract><abstract mxw-id="PA128500488" lang="EN" source="EPO" load-source="docdb"><p>The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.</p></abstract><description mxw-id="PDES63956545" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">RELATED APPLICATIONS</heading><p id="p0001" num="0001">This application claims the benefit of <patcit id="pcit0001" dnum="US61102177A"><text>U.S. Provisional Application No. 61/102,177, filed October 2, 2008</text></patcit> and <patcit id="pcit0002" dnum="US61222217A"><text>U.S. Provisional Application No. 61/222,217 filed July 1, 2009</text></patcit>. The entire teachings of the above applications are incorporated herein by reference.</p><heading id="h0002">BACKGROUND OF THE INVENTION</heading><p id="p0002" num="0002">A long-standing dilemma in tumor immunology is the ability of solid tumor cells to escape immune surveillance despite demonstrable antitumor T-cell response. Primarily, the immune evasion mechanism of tumor has been evaluated in the context of expression of immunosuppressive bio-molecules viz., IL-10, transforming growth factor-b (TGF-b), indoleamine-2,3-deoxygenase (IDO), macrophage colony stimulating factor (M-CSF), arginase, prostaglandin E2 (PGE2), cyclooxygenase-2 (COX2) and nitric-oxide synthase 2 (NOS2), IL-6, chemokine CXCL12 and the like, that inhibit the function of dendritic cells (DC) and T cells. The increased expression of death inducing molecules (FasL &amp; TRAIL), which induces apoptosis in tumor infiltrating T cells, has also been elucidated to explain the mechanism by which tumors evade the immune system.</p><p id="p0003" num="0003">The migration of immune cells to a target site is a major step in eliciting the immune response against tumor cell. Chemotaxis, or the oriented movement of a cell in response to a chemical agent, is a complex and highly integrated process. The movement can be positive (toward) or negative (away) from a chemical gradient. Movement toward an agent or stimulus is termed positive chemotaxis (i.e., the agent or stimulus is chemoattractive for the cell), while movement away from an agent or stimulus is termed negative chemotaxis (i.e., the agent or stimulus is chemorepulsive for the cell). It is believed that for both prokaryotes and eukaryotes, cells undergoing chemotaxis sense a change in agent concentration and, thereby, move in response to the concentration gradient. Chemoattraction (CA) and chemorepulsion<!-- EPO <DP n="2"> --> (CR) are therefore properties of the agent or stimulus, while chemotaxis is a property of cells.</p><p id="p0004" num="0004">The present inventors have discovered proteins which are expressed (secreted) by tumor cells which keep anti-tumor T cells (CD4 &amp; CD8), neutrophils, NK cells at the bay while concomitantly recruiting regulatory T cells at tumor sites and thus mediating evasion of the immune response. It would be advantageous to identify these proteins released from cancer cells that induce negative chemotaxis of immune cells and/or inhibit the activity of these proteins in order to induce positive chemotaxis of immune cells toward cancer cells.</p><heading id="h0003">SUMMARY OF THE INVENTION</heading><p id="p0005" num="0005">The present invention provides methods of inducing the migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.</p><p id="p0006" num="0006">In some embodiments, the activity of a chemorepellant released from a human cancer cell is inhibited. In other embodiments, the human cancer cell is selected from the group consisting of a renal adenocarcinoma cell, renal carcinoma cell, a glioblastoma cell a colon carcinoma cell, a hepatocellular carcinoma cell, an ovarian carcinoma cell and a prostate cancer cell.</p><p id="p0007" num="0007">In one embodiment, the activity of a chemorepellant released from the cancer cell is inhibited, wherein the chemorepellant comprises a sequence that has substantial identity to a protein isolated from ovarian cancer cystic fluid or to a biologically active fragment thereof, wherein the isolated protein or fragment thereof is capable of inducing chemorepulsion of an immune cell. In another embodiment, the chemorepellant comprises a sequence that has substantial identity to a protein isolated from a supernatant of a cell line or to a biologically active fragment thereof, wherein the cell line is selected from the group consisting of a human renal adenocarcinoma cell, a human renal carcinoma cell, a human glioblastoma cell, a human colon carcinoma cell, a human hepatocellular carcinoma cell, a human ovarian carcinoma cell and a human prostate cancer cell.</p><p id="p0008" num="0008">In another embodiment, the chemorepellant has substantial identity to the protein isolated from an ovarian cystic fluid, or to a biologically active fragment thereof. In another embodiment, the chemorepellant has substantial identity to of a<!-- EPO <DP n="3"> --> protein isolated from a supernatant of a cell line, or a biologically active fragment thereof, wherein the cell line is selected from the group consisting of a human renal adenocarcinoma cell, a human renal carcinoma cell, a human glioblastoma cell, a human colon carcinoma cell, a human hepatocellular carcinoma cell, a human ovarian carcinoma cell and a human prostate cancer cell.</p><p id="p0009" num="0009">In one embodiment, the chemorepellant has substantial identity to a protein selected from a chemorepellant protein set forth in Tables 1 to 9, or a biologically active fragment of thereof. In an additional embodiment, the chemorepellant has substantial identity to a protein selected from a protein set forth in Table 10 to 11, or a biologically active fragment thereof. In another embodiment, the chemorepellant has substantial identity to a protein selected from the group selected from the group consisting of actin, 14-3-3 zeta/delta, apolipoprotein A1, hemopexin, PARK7, cofilin-1, 14-3-3 epsilon, 14-3-3- gamma, phosphoserine phosphatase, superoxide dismutase, profilin-2, beta-2 microglobulin, cytochrome c, cystatin B, macrophage migration inhibitory factor (MIF), FK506 binding protein, thioredoxin, galectin 3, human transferrin, human EF-1-gamma and human galectin 3 binding protein, or a biologically active fragment of any of thereof.</p><p id="p0010" num="0010">In yet another embodiment, the invention is a method of treating cancer in a patient in need thereof comprising inhibiting the activity of a chemorepellant released from a cancer cell.</p><p id="p0011" num="0011">In a further embodiment, the invention is a method of inducing negative chemotaxis of a human immune cell comprising administering an inventive chemorepellant. In some embodiments, the chemorepellant comprises a sequence that has substantial identity to a protein isolated from ovarian cancer cystic fluid or to a biologically active fragment thereof, wherein the isolated protein or fragment thereof is capable of inducing chemorepulsion of an immune cell. In another embodiment, the invention is a method of inducing negative chemotaxis of a human immune cell comprising administering a chemorepellant, wherein the chemorepellant comprises a sequence that has substantial identity to a protein isolated from a supernatant of a cell line selected from the group consisting of a human renal adenocarcinoma cell, a human renal carcinoma cell, a human glioblastoma cell, a human colon carcinoma cell, a human hepatocellular carcinoma<!-- EPO <DP n="4"> --> cell, a human ovarian carcinoma cell and a human prostate cancer cell, or a biologically active fragment of said isolated protein, wherein said protein or fragment thereof is capable of inducing negative chemotaxis. In an additional embodiment, the administered chemorepellant comprises a sequence that has substantial identity to a protein listed in Tables 1 to 9, or to a biologically active fragment thereof. In an additional embodiment, the administered chemorepellant has substantial identity to a protein listed in Tables 10 to 11, or to a biologically active fragment thereof. In yet another embodiment, the administered chemorepellant comprises a sequence that has substantial identity to a protein selected from the group selected from the group consisting of actin, 14-3-3 zeta/delta, apolipoprotein A1, hemopexin, PARK7, cofilin-1, 14-3-3 epsilon, 14-3-3-gamma, phosphoserine phosphatase, superoxide dismutase, profilin-2, beta-2 microglobulin, cytochrome c, cystatin B, macrophage migration inhibitory factor (MIF), FK506 binding protein, thioredoxin, galectin 3, human transferrin, human EF-1-gamma and human galectin 3 binding protein, or a biologically active fragment thereof.</p><p id="p0012" num="0012">In yet another embodiment, the invention is a method of treating a condition mediated by migration of a human migratory cell toward a chemotactic site comprising administering to said patient a therapeutically effective amount of an inventive chemorepellant. In some embodiments, the chemorepellant comprises a sequence that has substantial identity to a protein isolated from ovarian cancer cystic fluid, or to a biologically active fragment thereof, wherein the isolated protein or fragment thereof is capable of inducing chemorepulsion of an immune cell. In a further embodiment, the invention is a method of treating a condition mediated by migration of a human migratory cell toward a chemotactic site comprising administering to said patient a therapeutically effective amount of a chemorepellant, wherein said chemorepellant comprises a sequence that has substantial identity to a protein isolated from a supernatant of a cell line selected from the group consisting of a human renal adenocarcinoma cell, a human renal carcinoma cell, a human glioblastoma cell, a human colon carcinoma cell, a human hepatocellular carcinoma cell, a human ovarian carcinoma cell and a human prostate cancer cell, or to a<!-- EPO <DP n="5"> --> biologically active fragment of any of thereof, wherein the protein or fragment thereof is capable of inducing negative chemotaxis of an immune cell.</p><p id="p0013" num="0013">These and other aspects of the invention, as well as various advantages and utilities, will be more apparent with reference to the drawings and the detailed description of the embodiments of the invention.</p><heading id="h0004">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p0014" num="0014"><ul><li><figref idrefs="f0001">FIG. 1</figref> is a bar graph showing fold induction (over media) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 1:30, 1:10, 1:3 and neat dilutions of ovarian cancer cyst fluid.</li><li><figref idrefs="f0002">FIG. 2</figref> is a bar graph showing fold induction (over media) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with S-200 chromatography fractions of cystic fluids.</li><li><figref idrefs="f0003">FIG. 3</figref> is a bar graph showing fold induction (over media) of chemorepulsion of neutrophils treated with 0.0011, 0.011, 0.11 and 1.1 uM actin (left) and 0.0018, 0.018, 0.18 and 1.8 uM 14-3-3 (right).</li><li><figref idrefs="f0004">FIG. 4</figref> is a bar graph showing fold induction (over media) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with a 1:1 combination of actin and 14-3-3 at 1:27, 1:9, 1:3 and neat dilutions.</li><li><figref idrefs="f0005">FIG. 5</figref> is a bar graph showing fold induction (over media) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.0051, 0.051, 0.51 and 5.1 uM apolipoprotein A1.</li><li><figref idrefs="f0006">FIG. 6</figref> is a bar graph showing fold induction (over media) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.0088, 0.088, 0.88 and 8.8 uM hemopexin.</li><li><figref idrefs="f0007">FIG. 7</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.15, 0.46, 1.39 and 4.16 uM Park-7.</li><li><figref idrefs="f0008">FIG. 8</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.28, 0.77, 2.30 and 6.9 uM cofilin-1.<!-- EPO <DP n="6"> --></li><li><figref idrefs="f0009">FIG. 9</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.43, 1.28, 3.83 and 11.48 uM 14-3-3 epsilon.</li><li><figref idrefs="f0010">FIG. 10</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.13, 0.39, 1.18, 3.53 uM 14-3-3 gamma.</li><li><figref idrefs="f0011">FIG. 11</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.15, 0.44, 1.33 and 3.99 uM phosphoserine phosphatase.</li><li><figref idrefs="f0012">FIG. 12</figref> is a bar graph showing fold induction (over media) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.32, 0.97, 2.92 and 8.76 uM superoxide dismutase.</li><li><figref idrefs="f0013">FIG. 13</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.28, 0.85, 2.56 and 7.68 uM profilin-2.</li><li><figref idrefs="f0014">FIG. 14</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.45, 1.36, 4.07 and 12.20 uM beta-2 microglobulin.</li><li><figref idrefs="f0015">FIG. 15</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 3, 9, 27 and 81.1 uM cytochrome C.</li><li><figref idrefs="f0016">FIG. 16</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.22, 0.66, 1.98 and 5.95 uM cystatin B.</li><li><figref idrefs="f0017">FIG. 17</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.16, 0.48, 1.43 and 4.3 uM macrophage inhibitor factor (MIF).</li><li><figref idrefs="f0018">FIG. 18</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.47, 1.41, 4.23 and 12.70 uM FKBP.<!-- EPO <DP n="7"> --></li><li><figref idrefs="f0019">FIG. 19</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 0.16, 0.48, 1.43 and 12.2 uM thioredoxin.</li><li><figref idrefs="f0020">FIG. 20</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with ACHN supernatant fractions collected from day 0 (d0) to day 4 (d4) and Turbodoma (used as controls).</li><li><figref idrefs="f0021">FIGs. 21A and B</figref> are bar graphs showing induction (number of cells per well) of chemorepulsion (B) and chemoattraction (A) of neutrophils treated with ACHN size exclusion fractions.</li><li><figref idrefs="f0022">FIG. 22</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with 786-O supernatant fractions collected from day 0 (d0) to day 4 (d4) and Turbodoma control (TD).</li><li><figref idrefs="f0023">FIGs. 23A and B</figref> are bar graphs showing induction (number of cells per well) of chemorepulsion (B) and chemoattraction (A) of neutrophils treated with 786-O size exclusion fractions.</li><li><figref idrefs="f0024">FIG. 24</figref> is a photograph of the SDS PAGE gel of supernatant fractions from ACHN and 786-O.</li><li><figref idrefs="f0025">FIG. 25</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with SF-359 supernatant fractions collected from day 2 (d2) to day 4 (d4) and TD control.</li><li><figref idrefs="f0026">FIGs. 26A and B</figref> are bar graphs showing fold induction (over media) (A) or number of cells (B) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with SF-359 size exclusion fractions.</li><li><figref idrefs="f0027">FIG. 27</figref> is a photograph of the SDS PAGE gel of supernatant fractions from SF-359 culture.</li><li><figref idrefs="f0028">FIG. 28</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) of neutrophils treated with U-251 supernatant fractions collected from day 0 (d0) to day 4 (d4) and TD control.<!-- EPO <DP n="8"> --></li><li><figref idrefs="f0029">FIGs. 29A and B</figref> are bar graphs showing induction (number of cells per well) of chemoattraction (A) and chemorepulsion (B) of neutrophils treated with U-251 size exclusion fractions.</li><li><figref idrefs="f0030">FIG. 30</figref> is a photograph of an SDS PAGE gel of supernatant fractions from U-251 supernatant fractions.</li><li><figref idrefs="f0031">FIG. 31</figref> is a bar graph showing induction (number of cells per well) of chemorepulsion (right) and chemoattraction (left) treated with HCC-2998 supernatants collected from day 0 (d0) to day 4 (d4) and TD control.</li><li><figref idrefs="f0032">FIGs. 32A and 32B</figref> are bar graphs showing induction (number of cells per well) of chemoattraction (A) and chemorepulsion (B) of neutrophils treated with HCC-2998 size exclusion fractions.</li><li><figref idrefs="f0033">FIG. 33</figref> is a bar graph showing fold induction (over media) of chemoattraction (left) and chemorepulsion (right) of HepG2 supernatant fractions collected from day 0 (d0) to day 7 (d7).</li><li><figref idrefs="f0034">FIG. 34</figref> is a bar graph showing fold induction (over media) of chemoattraction (left) and chemorepulsion (right) of HepG2 size exclusion fractions.</li><li><figref idrefs="f0035">FIG. 35</figref> is a bar graph showing fold induction (over media) of chemoattraction (left) or chemorepulsion (right) of neutrophils treated with CRL-1978 supernatants collected from day 0 (d0) to day 7 (d7) and TD control.</li><li><figref idrefs="f0036">FIG. 36</figref> is a bar graph showing fold induction (over media) of chemoattraction (left) or chemorepulsion (right) of neutrophils treated with CRL-1978 size exclusion fractions.</li><li><figref idrefs="f0037">FIG. 37</figref> is a bar graph showing fold induction (over media) of chemoattraction (left) or chemorepulsion (right) of neutrophils treated with PC3 supernatants from day 0 (d0) to day 7 (d7) and TD control.</li><li><figref idrefs="f0038">FIG. 38</figref> is a bar graph showing fold induction (over media) of chemoattraction (left) or chemorepulsion (right) of neutrophils treated with PC3 size exclusion fractions.</li><li><figref idrefs="f0039">FIG. 39</figref> is a bar graph showing RU of chemoattraction (left) and chemorepulsion (right) of neutrophils treated with SK-BR-3 anion exchange fractions (A2-A8) and media.<!-- EPO <DP n="9"> --></li><li><figref idrefs="f0040">FIG. 40</figref> is a photograph of a gel (Comassie Stain) of SK-BR-3 anion exchange fractions submitted for mass spectrometry (MS) analysis.</li></ul></p><heading id="h0005">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p0015" num="0015">A description of the embodiments of the invention follows.</p><p id="p0016" num="0016">As used herein, "a" or "an" are taken to mean one or more unless otherwise specified.</p><p id="p0017" num="0017">The present invention is based on the surprising discovery that one or more proteins isolated from ovarian cancer cystic fluid and/or from the supernatants of human cancer cell cultures induce negative chemotaxis of neutrophils. For example, as shown in Example 1, neutrophils contacted with certain chromatographic fractions of ovarian cancer cystic fluid showed greater than 9-fold induction of chemotaxis than that in response to media.</p><p id="p0018" num="0018">In one embodiment, the invention is a method of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell. In some embodiments, the cancer cell is selected from the group consisting of colon carcinoma cell, prostate cancer cell, breast cancer cell, lung cancer cell, skin cancer cell, liver cancer cell, bone cancer cell, pancreas cancer cell, ovarian cancer cell, testicular cancer cell, bladder cancer cell, kidney cancer cell, brain cancer cell, glioma cell, head and neck cancer cell. In another embodiment, the cancer cell is a renal adenocarcinoma cell, renal carcinoma cell, a glioblastoma cell a colon carcinoma cell, a hepatocellular carcinoma cell, an ovarian carcinoma cell and a prostate cancer cell.</p><p id="p0019" num="0019">According to the present method, migration of an immune cell toward a cancer cell can be induced by inhibiting the activity of a chemorepellant released from the cancer cell. The chemorepellant released from the cancer cell is a protein that induces negative chemotaxis of an immune cell. The inventive methods also encompass a method of inducing negative chemotaxis of an immune cell comprising administering a chemorepellant, wherein the chemorepellant comprises a sequence that has substantial identity to a protein release from a cancer cell, or a biologically active fragment thereof.</p><p id="p0020" num="0020">A "chemorepellant" is an agent or stimulus that induces, elicits or triggers negative chemotaxis of a migratory cell (movement away from an agent or<!-- EPO <DP n="10"> --> stimulus). In one embodiment, the chemorepellant comprises an amino acid sequence that has substantial identity to a protein isolated from ovarian cancer cystic fluid, or to a biologically active fragment thereof, wherein the isolated protein or fragment thereof is capable of inducing chemorepulsion of an immune cell. In another embodiment, the chemorepellant has substantial identity to a protein isolated from ovarian cancer cystic fluid or to a biologically active fragment thereof. In an additional embodiment, the chemorepellant has substantial identity to a protein isolated from ovarian cancer cystic fluid.</p><p id="p0021" num="0021">In another embodiment, the chemorepellant comprises a sequence that has substantial identity to a protein isolated from a supernatant of a cell line selected from the group consisting of a human renal adenocarcinoma cell, a human renal carcinoma cell, a human glioblastoma cell, a human colon carcinoma cell, a human hepatocellular carcinoma cell, a human ovarian carcinoma cell and a human prostate cancer cell, or a biologically active fragment of said isolated protein, wherein said protein or fragment thereof is capable of inducing negative chemotaxis. In yet another embodiment, the chemorepellant has substantial identity to a protein isolated from a supernatant of a cell line selected from the group consisting of a human renal adenocarcinoma cell, a human renal carcinoma cell, a human glioblastoma cell, a human colon carcinoma cell, a human hepatocellular carcinoma cell, a human ovarian carcinoma cell and a human prostate cancer cell, or a biologically active fragment of said isolated protein.</p><p id="p0022" num="0022">In yet another embodiment, the chemorepellant comprises a sequence that has substantial identity to a protein set forth in Tables 1 through 9 (shown below in Examples 1 to 3), or to a biologically active fragment thereof. In a further embodiment, the chemorepellant has substantial identity to a protein set forth in Tables 1 through 9, or a biologically active fragment thereof. In yet another embodiment, the chemorepellant is a protein set forth in Tables 1 through 9. In another embodiment, the chemorepellant is a protein set forth in Tables 10 to 11.</p><p id="p0023" num="0023">In an additional embodiment, the chemorepellant protein is a protein that is released by at least two distinct cancer cells. Cancer cells are distinct when they are of different origin or different cancer cell types. For example, liver cancer cells and ovarian cancer cells are distinct cancer cells. Similarly, a cancer cell of the kidney<!-- EPO <DP n="11"> --> cancer cell line, ACHN, is distinct from the kidney cancer cell line 786-O. In a further embodiment, the chemorepellant protein has substantial identity to a protein set forth in Tables 10-11, or to a biologically active fragment thereof.</p><p id="p0024" num="0024">In another embodiment, the chemorepellant comprises a sequence that has substantial identity to the amino acid sequence of a protein selected from the group consisting of actin, 14-3-3 zeta/delta, apolipoprotein A1, hemopexin, PARK7, cofilin-1, 14-3-3 epsilon, 14-3-3- gamma, phosphoserine phosphatase, superoxide dismutase, profilin-2, beta-2 microglobulin, cytochrome c, cystatin B, macrophage migration inhibitory factor (MIF), FK506 binding protein, thioredoxin, galectin 3, human transferrin, human EF-1-gamma and human galectin 3 binding protein, or a biologically active fragment of any of thereof. In an additional embodiment, the chemorepellant has substantial identity to a protein selected from the group consisting of actin, 14-3-3 zeta/delta, apolipoprotein A1, hemopexin, PARK7, cofilin-1, 14-3-3 epsilon, 14-3-3- gamma, phosphoserine phosphatase, superoxide dismutase, profilin-2, beta-2 microglobulin, cytochrome c, cystatin B, macrophage migration inhibitory factor (MIF), FK506 binding protein, thioredoxin, galectin 3, human transferrin, human EF-1-gamma and human galectin 3 binding protein. In a further embodiment, the chemorepellant is a protein selected from the group consisting of actin, 14-3-3 zeta/delta, apolipoprotein A1, hemopexin, PARK7, cofilin-1, 14-3-3 epsilon, 14-3-3- gamma, phosphoserine phosphatase, superoxide dismutase, profilin-2, beta-2 microglobulin, cytochrome c, cystatin B, macrophage migration inhibitory factor (MIF), FK506 binding protein, thioredoxin, galectin 3, human transferrin, human EF-1-gamma and human galectin 3 binding protein. Accession Numbers for these proteins are shown below in Tables 1 through 9.</p><p id="p0025" num="0025">A biologically active fragment is a peptide fragment of a naturally occurring protein or the full-length protein that retains at least some of the biological activity of the naturally occurring protein or the full-length protein. In some embodiments, the biological activity is the ability to induce chemorepulsion of a human migratory cell.</p><p id="p0026" num="0026">Ovarian cancer cystic fluid refers to cystic fluid from patients with ovarian carcinomas.<!-- EPO <DP n="12"> --></p><p id="p0027" num="0027">In some embodiments, the chemorepellant comprises a sequence that has substantial identity to a protein isolated from the supernatant of a cancer cell culture, wherein the culture is of a human cancer cell selected from the group consisting of a renal adenocarcinoma cell, renal carcinoma cell, a glioblastoma cell a colon carcinoma cell, a hepatocellular carcinoma cell, an ovarian carcinoma cell and a prostate cancer cell. In one embodiment, the human renal adenocarcinoma cell line is ACHN. In another embodiment, the human renal carcinoma cell line is 786-O. In another embodiment, the human glioblastoma cell line is SF539 or U251. In an additional embodiment, the human colon carcinoma cell line is HCC-2998. In a further embodiment, the human hepatocellular carcinoma cell line is HepG2 (ATCC No. HB-8065). In yet another embodiment, the human ovary clear cell carcinoma cell line is ATCC No. CRL-1978. In an additional embodiment, the human prostate cancer cell line is PC3 (ATCC No. CRL-1435).</p><p id="p0028" num="0028">In certain embodiments of the invention, the chemorepellant comprises a sequence that has substantial identity to the amino acid sequence of a protein isolated from ovarian cancer cystic fluid or the supernatant of a cancer cell line. In these embodiments, the ovarian cancer cystic fluid or supernatant is fractionated and the protein is isolated from a chemorepulsive fraction. A chemorepulsive fraction is a fraction that induces chemorepulsion of a human migratory cell. The ovarian cystic fluid or supernatant can be fractionated, for example, by size exclusion and anion exchange chromatography.</p><p id="p0029" num="0029">Exemplary amino acid sequences for actin, 14-3-3 zeta/delta, apolipoprotein A1, hemopexin, PARK7, cofilin-1, 14-3-3 epsilon, 14-3-3- gamma, phosphoserine phosphatase, superoxide dismutase, profilin-2, beta-2 microglobulin, cytochrome c, cystatin B, macrophage migration inhibitory factor (MIF), FK506 binding protein, thioredoxin, galectin 3, human transferrin, human EF-1-gamma and human galectin 3 binding protein are shown below:
<ul><li>Actin (IPI Acc. No. IPI100021439 (+2))
<img id="ib0001" file="imgb0001.tif" wi="142" he="19" img-content="dna" img-format="tif"/><!-- EPO <DP n="13"> -->
<img id="ib0002" file="imgb0002.tif" wi="142" he="35" img-content="dna" img-format="tif"/></li><li>14-3-3 (IPI Acc. No. IPI100021263 (+1))
<img id="ib0003" file="imgb0003.tif" wi="142" he="41" img-content="dna" img-format="tif"/></li><li>Apoliprotein A1 (SwissProt Acc. No. P02647)
<img id="ib0004" file="imgb0004.tif" wi="142" he="49" img-content="dna" img-format="tif"/></li><li>Hemopexin (SwissProt Acc. No. P02790)
<img id="ib0005" file="imgb0005.tif" wi="142" he="56" img-content="dna" img-format="tif"/><!-- EPO <DP n="14"> -->
<img id="ib0006" file="imgb0006.tif" wi="141" he="28" img-content="dna" img-format="tif"/></li><li>PARK-7 DJ1 (IPI Acc. No. IPI00298547)
<img id="ib0007" file="imgb0007.tif" wi="141" he="28" img-content="dna" img-format="tif"/></li><li>Cofilin-1 (IPI Acc. No. IPI00012011)
<img id="ib0008" file="imgb0008.tif" wi="142" he="28" img-content="dna" img-format="tif"/></li><li>14-3-3 epsilon (IPI Acc. No. IPI00000816)
<img id="ib0009" file="imgb0009.tif" wi="141" he="41" img-content="dna" img-format="tif"/></li><li>14-3-3- gamma (SwissProt. Acc. No. P61981; IPI Acc. No. IPI00220642)
<img id="ib0010" file="imgb0010.tif" wi="142" he="41" img-content="dna" img-format="tif"/><!-- EPO <DP n="15"> --></li><li>Phosphoserine Phosphatase, (IPI Acc. No. IPI00019178; UNIPROT Acc. No. Q5EY1)
<img id="ib0011" file="imgb0011.tif" wi="141" he="35" img-content="dna" img-format="tif"/></li><li>Superoxide dismutase (IPI Acc. No. IPI00218733)
<img id="ib0012" file="imgb0012.tif" wi="141" he="35" img-content="dna" img-format="tif"/></li><li>Profilin-2 (IPI Acc. No. IPI00219468)
<img id="ib0013" file="imgb0013.tif" wi="141" he="28" img-content="dna" img-format="tif"/></li><li>Beta-2 microglobulin (IPI Acc. No. IPI00004656)
<img id="ib0014" file="imgb0014.tif" wi="141" he="20" img-content="dna" img-format="tif"/></li><li>Cytochrome C (IPI Acc. No. IPI100465315)
<img id="ib0015" file="imgb0015.tif" wi="142" he="19" img-content="dna" img-format="tif"/><!-- EPO <DP n="16"> --></li><li>Cystatin B (IPI Acc. No. IPI00021828)
<img id="ib0016" file="imgb0016.tif" wi="141" he="19" img-content="dna" img-format="tif"/></li><li>Macrophage migration inhibitory factor (MIF) (IPI Acc. No. IPI00293276)
<img id="ib0017" file="imgb0017.tif" wi="142" he="19" img-content="dna" img-format="tif"/></li><li>FK506 binding protein (IPI Acc. No IPI00873810)
<img id="ib0018" file="imgb0018.tif" wi="141" he="20" img-content="dna" img-format="tif"/></li><li>Thioredoxin (IPI Acc. No. IPI00216298)
<img id="ib0019" file="imgb0019.tif" wi="141" he="19" img-content="dna" img-format="tif"/></li><li>Galectin 3 (IPI Acc. No. IPI00465431)
<img id="ib0020" file="imgb0020.tif" wi="141" he="49" img-content="dna" img-format="tif"/></li><li>Transferrin (TRFE_HU Serotransferrin precursor) (Acc. No. P02787)
<img id="ib0021" file="imgb0021.tif" wi="119" he="19" img-content="dna" img-format="tif"/><!-- EPO <DP n="17"> -->
<img id="ib0022" file="imgb0022.tif" wi="142" he="105" img-content="dna" img-format="tif"/></li><li>EF-1-gamma (EF1G-HU Elongation factor 1-gamma) (Acc. No. P26641)
<img id="ib0023" file="imgb0023.tif" wi="141" he="77" img-content="dna" img-format="tif"/></li><li>Galectin-3 binding protein (LG3BP_HU galectin 3 binding protein precursor) (Acc. No. Q08380<!-- EPO <DP n="18"> -->
<img id="ib0024" file="imgb0024.tif" wi="142" he="92" img-content="dna" img-format="tif"/></li></ul></p><p id="p0030" num="0030">As used herein, a chemorepellant has "substantial identity" to another protein when the chemorepellant has an amino acid sequence that has at least about 60 percent sequence identity, at least about 70 percent sequence identity, at least about 80 percent sequence identity, at least about 85 percent sequence identity, at least about 85 to 95 percent sequence identity, at least about 90 to about 95 percent sequence identity, at least about 98 percent sequence identity, or at least about 99 percent sequence identity to the amino acid sequence of the other protein. The terms "sequence identity" or "identity" in reference to a sequence refers to sequence identity between two amino acid sequences or between two nucleotide sequences. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. The terms "sequence homology" or "homology" in reference to a sequence refers to sequence homology between two amino acid sequences or two nucleotide sequences. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of homology, similarity, or identity refers to a function<!-- EPO <DP n="19"> --> of the number of identical or similar amino acids at positions shared by the compared sequences. Expression as a percentage of homology, similarity, or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. Various alignment algorithms and/or programs may be used, including FASTA, BLAST, or ENTREZ. FASTA and BLAST are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default settings. ENTREZ is available through the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Md. In one embodiment, the percent identity of two sequences can be determined by the GCG program with a gap weight of 1, e.g., each amino acid gap is weighted as if it were a single amino acid or nucleotide mismatch between the two sequences.</p><p id="p0031" num="0031">A "chemoattractant" is an agent or stimulus that induces, elicits or triggers positive chemotaxis (movement towards an agent or stimulus) by a migratory cell.</p><p id="p0032" num="0032">As used herein the terms "induce," "elicit," and "trigger," when referring to the activity of a chemorepellant or chemoattractant with respect to negative or positive chemotaxis, carry the same meaning.</p><p id="p0033" num="0033">The activity of the chemorepellant released from a cancer cell is inhibited when the ability of the chemorepellant to induce negative chemotaxis of the immune cell is suppressed or decreased. According to the current invention, the activity of the chemorepellant released from the cancer cell can be inhibited by any means that suppresses negative chemotaxis of the immune cell or that induces positive chemotaxis of the immune cell toward the cancer cell. For example, the activity of the chemorepellant can be inhibited by administering an agent that inhibits the activity of the chemorepellants. Such agents, include, but are not limited to, small molecules, proteins, antibodies, and antisense nucleic acids.</p><p id="p0034" num="0034">In one embodiment, the activity of the chemorepellant released from a cancer cell is inhibited when the release of the chemorepellant is suppressed or decreased. In another embodiment, the activity of the chemorepellant released from a cancer cell is inhibited by administering an agent that binds to the chemorepellant and inhibits its activity. In some embodiments, the activity of the chemorepellant is inhibited by administering an antibody that binds the chemorepellant and inhibits<!-- EPO <DP n="20"> --> chemorepellant activity. The term "antibody" as used herein refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The term antibody, as used herein, includes antibody fragments either produced by modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv)(scFv) or those identified using phase display libraries (see, for example, <nplcit id="ncit0001" npl-type="s"><text>McCafferty et al. (1990) Nature 348:552-554</text></nplcit>). The term antibody also encompasses both monoclonal and polyclonal antibodies. The terms polyclonal and monoclonal refer to the degree of homogeneity of an antibody preparation, and are not intended to be limited to particular methods of production. In one embodiment, the antibody does not bind other proteins or molecules other than the chemorepellant.</p><p id="p0035" num="0035">Antibodies can be raised against an appropriate immunogen, including a chemorepellant released from a cancer cell or a fragment thereof. Preparation of immunizing antigen, and polyclonal and monoclonal antibody production can be performed using any suitable technique. A variety of methods have been described (see e.g., <nplcit id="ncit0002" npl-type="s"><text>Kohler et al., Nature, 256:495-497 (1975</text></nplcit>) and <nplcit id="ncit0003" npl-type="s"><text>Eur. J. Immunol. 6:511-519 (1976</text></nplcit>); <nplcit id="ncit0004" npl-type="s"><text>Milstein et al., Nature 266:550-552 (1977</text></nplcit>); <patcit id="pcit0003" dnum="US4172124A"><text>Koprowski et al., U.S. Pat. No. 4,172,124</text></patcit>; <nplcit id="ncit0005" npl-type="b"><text>Harlow, E. and D. Lane, 1988, Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y</text></nplcit>.); and <nplcit id="ncit0006" npl-type="b"><text>Current Protocols In Molecular Biology, Vol. 2 (Supplement 27, Summer '94), Ausubel, F. M. et al., Eds., (John Wiley &amp; Sons: New York, N.Y.), Chapter 11, 1991</text></nplcit>); the teachings of each of which are incorporated herein by reference). Other suitable methods of producing or isolating antibodies of the requisite specificity can used, including, for example, methods which select recombinant antibody from a library, or which rely upon immunization of transgenic animals (e.g., mice) capable of producing a full repertoire of human antibodies (see e.g., <nplcit id="ncit0007" npl-type="s"><text>Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 2555 (1993</text></nplcit>); <nplcit id="ncit0008" npl-type="s"><text>Jakobovits et al., Nature, 362:255 258 (1993</text></nplcit>); <patcit id="pcit0004" dnum="US5545806A"><text>Lonberg et al., U.S. Pat. No. 5,545,806</text></patcit>; and <patcit id="pcit0005" dnum="US5545807A"><text>Surani et al., U.S. Pat. No. 5,545,807</text></patcit>; the teachings of which are each incorporated herein by reference). Single-chain antibodies, and chimeric, humanized or primatized (CDR-grafted), or veneered antibodies, as well as chimeric, CDR-grafted or veneered single-chain antibodies, comprising portions derived from different species, and the like are also<!-- EPO <DP n="21"> --> encompassed by the present invention and the term "antibody." The various portions of these antibodies can be joined together chemically by conventional techniques, or can be prepared as a contiguous protein using genetic engineering techniques. For example, nucleic acids encoding a chimeric or humanized chain can be expressed to produce a contiguous protein. See, e.g., <patcit id="pcit0006" dnum="US4816567A"><text>Cabilly et al., U.S. Pat. No. 4,816,567</text></patcit>; Cabilly et al., European Patent No. <patcit id="pcit0007" dnum="EP0125023B1"><text>0 125 023 B1</text></patcit>; <patcit id="pcit0008" dnum="US4816397A"><text>Boss et al., U.S. Pat. No. 4,816,397</text></patcit>; Boss et al., European Patent No. <patcit id="pcit0009" dnum="EP0120694B1"><text>0 120 694 B1</text></patcit>; <patcit id="pcit0010" dnum="WO8601533A"><text>Neuberger, M. S. et al., WO 86/01533</text></patcit>; Neuberger, M. S. et al., European Patent No. <patcit id="pcit0011" dnum="EP0194276B1"><text>0 194 276 B1</text></patcit>; <patcit id="pcit0012" dnum="US5225539A"><text>Winter, U.S. Pat. No. 5,225,539</text></patcit>; Winter, European Patent No. <patcit id="pcit0013" dnum="EP0239400B1"><text>0 239 400 B1</text></patcit>; Queen et al., European Patent No. <patcit id="pcit0014" dnum="EP0451216B1"><text>0 451 216 B1</text></patcit>; and <patcit id="pcit0015" dnum="EP0519596A1"><text>Padlan et al., EP 0 519 596 A1</text></patcit>. See also, <nplcit id="ncit0009" npl-type="s"><text>Newman et al., BioTechnology, 10:1455 1460 (1992</text></nplcit>), regarding primatized antibody, and <patcit id="pcit0016" dnum="US4946778A"><text>Ladner et al., U.S. Pat. No. 4,946,778</text></patcit> and <nplcit id="ncit0010" npl-type="s"><text>Bird et al., Science, 242:423 426 (1988</text></nplcit>) regarding single-chain antibodies. In addition, antigen-binding fragments of antibodies, including fragments of chimeric, humanized, primatized, veneered or single-chain antibodies, can also be produced, including, but not limited to, Fv, Fab, Fab' and F(ab')<sub>2</sub> fragments are encompassed by the invention.</p><p id="p0036" num="0036">In another embodiment, the activity of the chemorepellant is inhibited by administering an antisense nucleic acid. In this context, the chemorepellant antisense nucleic acid comprises at least six nucleotides that are antisense to a gene or cDNA encoding the chemorepellant released from a cancer cell or a portion thereof. The antisense nucleic acid is capable of hybridizing to a portion of an RNA encoding the chemorepellant. The antisense nucleic acid is a double-stranded or single-stranded oligonucleotide, RNA or DNA or a modification or derivative thereof, and can be directly administered to a cell or produced intracellularly by transcription of exogenous, introduced sequences. In one embodiment, the antisense nucleic acid has from about 6 to about 50 nucleotides. In other embodiment, the antisense nucleic acid has at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 200 nucleotides. The antisense nucleic acid can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof and can be single-stranded or double-stranded. In addition, the antisense molecules can be polymers that are nucleic acid mimics, such as PNA, morpholino oligos, and LNA.<!-- EPO <DP n="22"> --> Other types of antisense molecules include short double-stranded RNAs, known as siRNAs, and short hairpin RNAs, and long dsRNA (greater than 50 base pairs).</p><p id="p0037" num="0037">In yet another embodiment, the activity of the chemorepellant is inhibited by administering a ribozyme molecule that is designed to catalytically cleave gene mRNA transcripts encoding the chemorepellant. Ribozymes thus prevents translation of the target mRNA and prevents expression of the gene product. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage event. The composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage.</p><p id="p0038" num="0038">In another embodiment, the invention is a method of treating cancer in a patient suffering therefrom comprising inducing migration of an immune cell toward a cancer cell by inhibiting the activity of a chemorepellant released from a cancer cell. "Treating" or "treatment" includes preventing or delaying the onset of the symptoms, complications, or biochemical indicia of a disease, alleviating or ameliorating the symptoms or arresting or inhibiting further development of the disease, condition, or disorder. A "patient" refers to a human subject in need of treatment.</p><p id="p0039" num="0039">In specific embodiments, the cancer is a solid tumor. In one embodiment, the solid tumor is selected from the group consisting of colon, prostate, breast, lung, skin, liver, bone, pancreas, ovary, testis, bladder, kidney, brain, head and neck cancer. As used herein, a "therapeutically effective amount" in reference to inhibition of a chemorepellant is an amount sufficient to inhibit negative migration of an immune cell and ameliorate a disease or condition of a patient or achieve a desired outcome.</p><p id="p0040" num="0040">In reference to inducing chemotaxis, a "therapeutically effective amount" is an amount sufficient to induce negative migration of a migratory cell and ameliorate a disease or condition of a patient or achieve a desired outcome.</p><p id="p0041" num="0041">As used herein, "migratory cells" are those cells which are capable of movement from one place to another in response to a stimulus. Human migratory<!-- EPO <DP n="23"> --> cells include those involved in the processes of cancer, immunity, angiogenesis or inflammation and also include those identified to play a role in other disease states or conditions. Migratory cells include, but are not limited to, immune cells, hematopoietic cells, neural cells, epithelial cells, mesenchymal cells, stem cells, germ cells and cells involved in angiogenesis.</p><p id="p0042" num="0042">Immune cells include, but are not limited to, monocytes, Natural Killer (NK) cells, dendritic cells (which could be immature or mature), subsets of dendritic cells including myeloid, plasmacytoid (also called lymphoid) or Langerhans; macrophages such as histiocytes, Kupffer's cells, alveolar macrophages or peritoneal macrophages; neutrophils, eosinophils, mast cells, basophils; B cells including plasma B cells, memory B cells, B-1 cells, B-2 cells; CD45RO (naive T), CD45RA (memory T); CD4 Helper T Cells including Th1, Th2 and Tr1/Th3; CD8 Cytotoxic T Cells, Regulatory T Cells and Gamma Delta T Cells.</p><p id="p0043" num="0043">Hematopoietic cells include, but are not limited to, pluripotent stem cells, multipotent progenitor cells and/or progenitor cells committed to specific hematopoietic lineages. The progenitor cells committed to specific hematopoietic lineages can be of T cell lineage, B cell lineage, dendritic cell lineage, neutrophil lineage, Langerhans cell lineage and/or lymphoid tissue-specific macrophage cell lineage. The hematopoietic cells can be derived from a tissue such as bone marrow, peripheral blood (including mobilized peripheral blood), umbilical cord blood, placental blood, fetal liver, embryonic cells (including embryonic stem cells), aortal-gonadal-mesonephros derived cells, and lymphoid soft tissue. Lymphoid soft tissue includes the thymus, spleen, liver, lymph node, skin, tonsil and Peyer's patches. In other embodiments, hematopoietic cells can be derived from in vitro cultures of any of the foregoing cells, and in particular in vitro cultures of progenitor cells.</p><p id="p0044" num="0044">Neural cells are cells of neural origin and include neurons and glia and/or cells of both central and peripheral nervous tissue.</p><p id="p0045" num="0045">Epithelial cells include cells of a tissue that covers and lines the free surfaces of the body. Such epithelial tissue includes cells of the skin and sensory organs, as well as the specialized cells lining the blood vessels, gastrointestinal tract, air passages, lungs, ducts of the kidneys and endocrine organs.<!-- EPO <DP n="24"> --></p><p id="p0046" num="0046">Mesenchymal cells include, but are not limited to, cells that express typical fibroblast markers such as collagen, vimentin and fibronectin.</p><p id="p0047" num="0047">Cells involved in angiogenesis are cells that are involved in blood vessel formation and include cells of endothelial origin and cells of mesenchymal origin.</p><p id="p0048" num="0048">Germ cells are cells specialized to produce haploid gametes.</p><p id="p0049" num="0049">In certain embodiment, the human migratory cell is an immune cell. In other embodiments, the immune cell is selected from the group consisting of lymphocytes, monocytes, neutrophils, eosinophils and mast cells. In a further embodiment, the immune cell is a neutrophil or an eosinophil.</p><p id="p0050" num="0050">As used herein, the terms "contact" or "contacting" means the act of touching or bringing together two entities or things in such proximity as will allow an influence of at least one on the other. The definition, while inclusive of physical contact is not so limited.</p><p id="p0051" num="0051">Based on their ability to induce negative chemotaxis, the chemorepellant proteins or biologically active fragments thereof as described herein are useful for inhibiting the induction of chemotaxis of migratory cells toward a chemotactic site. In one embodiment, the chemorepellant comprises a sequence that has substantial identity to the amino acid sequence of a protein selected from the proteins set forth in Tables 1 to 9, or to a biologically active fragment thereof. In some embodiment, the chemorepellant protein comprises a sequence that has substantial identity to a protein selected from the proteins set forth in Tables 10 to 11, or to a biologically active fragment thereof. In another embodiment, the protein comprises a sequence that has substantial identity to the sequence of a protein selected from the group consisting of actin, 14-3-3 zeta/delta, apolipoprotein A1, hemopexin, PARK7, cofilin-1, 14-3-3 epsilon, 14-3-3- gamma, phosphoserine phosphatase, superoxide dismutase, profilin-2, beta-2 microglobulin, cytochrome c, cystatin B, macrophage migration inhibitory factor (MIF), FK506 binding protein, thioredoxin, galectin 3, human transferrin, human EF-1-gamma and human galectin 3 binding protein, or to a biologically active fragment of any of thereof. As used herein, a "chemotactic site" is a site that induces positive chemotaxis of migratory cells. Chemotactic sites include sites of inflammation, medical implants, transplants and angiogenesis.<!-- EPO <DP n="25"> --></p><p id="p0052" num="0052">The chemorepellants described herein are useful for inhibiting the induction of chemotaxis of migratory cells toward a site of inflammation. Inhibiting migratory cell chemotaxis toward a site of inflammation can result in a reduction or amelioration of an inflammatory response in situations such as bacterial infection, tissue injury-induced inflammation (e.g., ischemia-reperfusion injury), complement-induced inflammation, oxidative stress (e.g., hemodialysis), immune complex-induced inflammation (e.g., antibody-mediated glomerunephritis), cytokine-induced inflammation (e.g., rheumatoid arthritis), antineutrophil cytoplasmic antibodies and vasculitis (e.g, autoimmunity against neutrophil components), genetic disorders of neutrophil regulations (e.g., hereditary periodic fever syndromes), implant related inflammation, and cystic fibrosis.</p><p id="p0053" num="0053">In certain embodiments, the invention is a method of treating an inflammatory condition in a patient suffering therefrom comprising administering to said patient a therapeutically effective amount of a chemorepellant described herein. In certain other embodiments, the invention is a method of treating an inflammatory condition in a patient suffering therefrom comprising administering to said patient a therapeutically effective amount of a chemorepellant described herein. Inflammatory conditions include, but are not limited to, appendicitis, peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, acute or ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, inflammatory bowel disease (including, for example, Crohn's disease and ulcerative colitis), enteritis, Whipple's disease, asthma, chronic obstructive pulmonary disease, acute lung injury, ileus (including, for example, post-operative ileus), allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, cystic fibrosis, pneumonitis, pneumoultramicroscopic silicovolcanoconiosis, alvealitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, influenza, respiratory syncytial virus, herpes, disseminated bacteremia, Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cysts, bums, dermatitis, dermatomyositis, urticaria, acne, vasulitis, angiitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial<!-- EPO <DP n="26"> --> ischemia, periarteritis nodosa, rheumatic fever, Alzheimer's disease, celiac disease, congestive heart failure, adult respiratory distress syndrome, meningitis, encephalitis, multiple sclerosis, cerebral infarction, cerebral embolism, Guillan-Barre syndrome, neuritis, neuralgia, uveitis, arthritides, arthralgias, osteomyelitis, fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thryoiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcet's syndrome, allograft rejection, graft-versus-host disease, Type I diabetes, ankylosing spondylitis, Berger's disease, Type II diabetes, Retier's syndrome, Hodgkins disease and injection site reaction.</p><p id="p0054" num="0054">Injection site reaction is a term generally used to describe inflammation in and around a site of injection. Injection site reaction has been observed with the injection of numerous pharmaceutical agents including, but not limited, chemotherapeutic drugs, immunomodulator drugs, and vaccines. The present invention encompasses a method for the treatment or reduction of injection site reaction comprising administration of a chemorepellant described herein to the injection site. The chemorepellant can, for example, be administered before, during or after injection. In some embodiments, exenatide or analog thereof can be administered topically at the site of the injection.</p><p id="p0055" num="0055">In another embodiment, the invention is a method of inhibiting positive chemotaxis toward a medical implant. The medical implant can be contacted or coated with a chemorepellant described herein. The proteins can also be administered locally at the site of the medical implant. A medical implant is defined as a device or entity implanted into a surgically or naturally formed cavity of the body. Medical implants include, but are not limited to, stents, pacemakers, pacemaker leads, defibrillators, drug delivery devices, sensors, pumps, embolization coils, sutures, electrodes, cardiovascular implants, arterial stents, heart valves, orthopedic implants, dental implants, bone screws, plates, catheters, cannulas, plugs, fillers, constrictors, sheets, bone anchors, plates, rods, seeds, tubes, or portions thereof. In addition to the chemorepellant, the medical implant can be coated with a cell-growth potentiating agent, an anti-infective agent and/or an anti-inflammatory agent.<!-- EPO <DP n="27"> --></p><p id="p0056" num="0056">In yet another embodiment, the invention is a method of inhibiting positive chemotaxis toward an organ transplant or tissue graft. Organ transplants and tissue grants include, but are not limited to, renal, pancreatic, hepatic, lymphoid and cardiac grafts and organs. Lymphoid grafts include a splenic graft, a lymph node derived graft, a Peyer's patch derived graft, a thymic graft and a bone marrow derived graft. In an additional embodiment, the invention is a method of treating a patient suffering from transplant or graft rejection comprising administering an inventive chemorepellant.</p><p id="p0057" num="0057">As discussed above, the inventive chemorepellants can be used to inhibit chemotaxis toward a site of angiogenesis. A site of angiogenesis is a site where blood vessels are being formed. In one embodiment, the invention is a method of inducing negative chemotaxis of endothelial cells away from a site of angiogenesis. The invention also encompasses a method of inhibiting angiogenesis in a patient in need thereof comprising administering an inventive chemorepellant In a further embodiment, the invention is a method of treating cancer or a tumor comprising administering an inventive chemorepellant in an amount effective to inhibit angiogenesis. According to another aspect of the invention, a method of inhibiting endothelial cell migration to a tumor site in a subject is provided. The method involves locally administering to or contacting an area surrounding a tumor site in need of such treatment an inventive chemorepellant in an amount effective to inhibit endothelial cell migration into the tumor site in the subject.</p><p id="p0058" num="0058">Exemplary cancers and tumors that can be treated according to the methods of the invention include, for example, biliary tract cancer; brain cancer including glioblastomas and medulloblastomas; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer, gastric cancer; hematological neoplasms, including acute lymphocytic and myelogenous leukemia; multiple myeloma; AIDS associated leukemias and adult T-cell leukemia lymphoma; intraepithelial neoplasms, including Bowen's disease and Paget's disease; liver cancer (hepatocarcinoma); lung cancer; lymphomas, including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer, including squamous cell carcinoma; ovarian cancer, including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells; pancreas cancer;<!-- EPO <DP n="28"> --> prostate cancer; rectal cancer; sarcomas, including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma and osteosarcoma; skin cancer, including melanoma, Kaposi's sarcoma, basocellular cancer and squamous cell cancer; testicular cancer, including germinal tumors (seminoma, non-seminoma [teratomas, choriocarcinomas]), stromal tumors and germ cell tumors; thyroid cancer, including thyroid adenocarcinoma and medullar carcinoma; and renal cancer including adenocarcinoma and Wilms tumor.</p><p id="p0059" num="0059">The invention also encompasses a method of contraception in a patient in need thereof comprising administering an inventive chemorepellant in an amount effective to inhibit migration of germ cells in the subject. According to another aspect of the invention, a method of treating infertililty and premature labor is provided. The method comprises administering a compound described above in an amount effective to inhibit immune cells from migrating close to a germ cell in the subject.</p><p id="p0060" num="0060">The treatment methods disclosed herein involve administering, either locally or systemically, to a selected site in a subject in need of such a treatment a chemorepellant of the invention in an amount effective to induce negative chemotaxis of a human migratory cell or an inhibitor of a chemorepellant in an amount effect to suppress negative chemotaxis of an immune cell. For example, a "therapeutically effective amount" in reference to the treatment of an inflammatory condition encompasses an amount sufficient to induce negative chemotaxis of an immune cell and/or ameliorate a symptom of the inflammatory condition.</p><p id="p0061" num="0061">In certain embodiments, the chemorepellant can be co-administered with a second agent (e.g., another chemoattractant or with any drug or agent which is not itself a chemoattractant). Co-administered agents, compounds, chemoattractants or therapeutics need not be administered at exactly the same time. In certain embodiments, however, the chemorepellant is administered substantially simultaneously as the second agent. By "substantially simultaneously," it is meant that the chemorepellant is administered before, at the same time, and/or after the administration of the second agent. Second agents include, for example, anti-inflammatory agents, anti-cancer agents, anti-infective agents, immune therapeutics (immunosuppresants) and other therapeutic compounds. A second agent can be<!-- EPO <DP n="29"> --> chosen based on the condition or disease to be treated. For example, in a method of treating cancer or a tumor, the chemorepellant can be administered with an anti-cancer agent. Similarly, in a method of treating an inflammatory condition, the chemorepellant can be administered with an anti-inflammatory agent, an anti-infective agent or an immunosuppressant.</p><p id="p0062" num="0062">An anti-infective agent is an agent which reduces the activity of or kills a microorganism and includes: Aztreonam; Chlorhexidine Gluconate; Imidurea; Lycetamine; Nibroxane; Pirazmonam Sodium; Propionic Acid; Pyrithione Sodium; Sanguinarium Chloride; Tigemonam Dicholine; Acedapsone; Acetosulfone Sodium; Alamecin; Alexidine; Amdinocillin; Amdinocillin Pivoxil; Amicycline; Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin Sulfate; Aminosalicylic acid; Aminosalicylate sodium; Amoxicillin; Amphomycin; Ampicillin; Ampicillin Sodium; Apalcillin Sodium; Apramycin; Aspartocin; Astromicin Sulfate; Avilamycin; Avoparcin; Azithromycin; Azlocillin; Azlocillin Sodium; Bacampicillin Hydrochloride; Bacitracin; Bacitracin Methylene Disalicylate; Bacitracin Zinc; Bambermycins; Benzoylpas Calcium; Berythromycin; Betamicin Sulfate; Biapenem; Biniramycin; Biphenamine Hydrochloride; Bispyrithione Magsulfex; Butikacin; Butirosin Sulfate; Capreomycin Sulfate; Carbadox; Carbenicillin Disodium; Carbenicillin Indanyl Sodium; Carbenicillin Phenyl Sodium; Carbenicillin Potassium; Carumonam Sodium; Cefaclor; Cefadroxil; Cefamandole; Cefamandole Nafate; Cefamandole Sodium; Cefaparole; Cefatrizine; Cefazaflur Sodium; Cefazolin; Cefazolin Sodium; Cefbuperazone; Cefdinir; Cefepime; Cefepime Hydrochloride; Cefetecol; Cefixime; Cefinenoxime Hydrochloride; Cefmetazole; Cefmetazole Sodium; Cefonicid Monosodium; Cefonicid Sodium; Cefoperazone Sodium; Ceforanide; Cefotaxime Sodium; Cefotetan; Cefotetan Disodium; Cefotiam Hydrochloride; Cefoxitin; Cefoxitin Sodium; Cefpimizole; Cefpimizole Sodium; Cefpiramide; Cefpiramide Sodium; Cefpirome Sulfate; Cefpodoxime Proxetil; Cefprozil; Cefroxadine; Cefsulodin Sodium; Ceftazidime; Ceftibuten; Ceftizoxime Sodium; Ceftriaxone Sodium; Cefuroxime; Cefuroxime Axetil; Cefuroxime Pivoxetil; Cefuroxime Sodium; Cephacetrile Sodium; Cephalexin; Cephalexin Hydrochloride; Cephaloglycin; Cephaloridine; Cephalothin Sodium; Cephapirin Sodium; Cephradine; Cetocycline<!-- EPO <DP n="30"> --> Hydrochloride; Cetophenicol; Chloramphenicol; Chloramphenicol Palmitate; Chloramphenicol Pantothenate Complex; Chloramphenicol Sodium Succinate; Chlorhexidine Phosphanilate; Chloroxylenol; Chlortetracycline Bisulfate; Chlortetracycline Hydrochloride; Cinoxacin; Ciprofloxacin; Ciprofloxacin Hydrochloride; Cirolemycin; Clarithromycin; Clinafloxacin Hydrochloride; Clindamycin; Clindamycin Hydrochloride; Clindamycin Palmitate Hydrochloride; Clindamycin Phosphate; Clofazimine; Cloxacillin Benzathine; Cloxacillin Sodium; Cloxyquin; Colistimethate Sodium; Colistin Sulfate; Coumermycin; Coumermycin Sodium; Cyclacillin; Cycloserine; Dalfopristin; Dapsone; Daptomycin; Demeclocycline; Demeclocycline Hydrochloride; Demecycline; Denofungin; Diaveridine; Dicloxacillin; Dicloxacillin Sodium; Dihydrostreptomycin Sulfate; Dipyrithione; Dirithromycin; Doxycycline; Doxycycline Calcium; Doxycycline Fosfatex; Doxycycline Hyclate; Droxacin Sodium; Enoxacin; Epicillin; Epitetracycline Hydrochloride; Erythromycin; Erythromycin Acistrate; Erythromycin Estolate; Erythromycin Ethylsuccinate; Erythromycin Gluceptate; Erythromycin Lactobionate; Erythromycin Propionate; Erythromycin Stearate; Ethambutol Hydrochloride; Ethionamide; Fleroxacin; Floxacillin; Fludalanine; Flumequine; Fosfomycin; Fosfomycin Tromethamine; Fumoxicillin; Furazolium Chloride; Furazolium Tartrate; Fusidate Sodium; Fusidic Acid; Gentamicin Sulfate; Gloximonam; Gramicidin; Haloprogin; Hetacillin; Hetacillin Potassium; Hexedine; Ibafloxacin; Imipenem; Isoconazole; Isepamicin; Isoniazid; Josamycin; Kanamycin Sulfate; Kitasamycin; Levofuraltadone; Levopropylcillin Potassium; Lexithromycin; Lincomycin; Lincomycin Hydrochloride; Lomefloxacin; Lomefloxacin Hydrochloride; Lomefloxacin Mesylate; Loracarbef; Mafenide; Meclocycline; Meclocycline Sulfosalicylate; Megalomicin Potassium Phosphate; Mequidox; Meropenem; Methacycline; Methacycline Hydrochloride; Methenamine; Methenamine Hippurate; Methenamine Mandelate; Methicillin Sodium; Metioprim; Metronidazole Hydrochloride; Metronidazole Phosphate; Mezlocillin; Mezlocillin Sodium; Minocycline; Minocycline Hydrochloride; Mirincamycin lydrochloride; Monensin; Monensin Sodium; Nafcillin Sodium; Nalidixate Sodium; Nalidixic Acid; Natamycin; Nebramycin; Neomycin Palmitate; Neomycin Sulfate; Neomycin Undecylenate; Netilmicin Sulfate; Neutramycin; Nifuradene; Nifuraldezone;<!-- EPO <DP n="31"> --> Nifuratel; Nifuratrone; Nifurdazil; Nifurimide; Nifurpirinol; Nifurquinazol; Nifurthiazole; Nitrocycline; Nitrofurantoin; Nitromide; Norfloxacin; Novobiocin Sodium; Ofloxacin; Ormetoprim; Oxacillin Sodium; Oximonam; Oximonam Sodium; Oxolinic Acid; Oxytetracycline; Oxytetracycline Calcium; Oxytetracycline Hydrochloride; Paldimycin; Parachlorophenol; Paulomycin; Pefloxacin; Pefloxacin Mesylate; Penamecillin; Penicillin G Benzathine; Penicillin G Potassium; Penicillin G Procaine; Penicillin G Sodium; Penicillin V; Penicillin V Benzathine; Penicillin V Hydrabamine; Penicillin V Potassium; Pentizidone Sodium; Phenyl Aminosalicylate; Piperacillin Sodium; Pirbenicillin Sodium; Piridicillin Sodium; Pirlimycin Hydrochloride; Pivampicillin Hydrochloride; Pivampicillin Pamoate; Pivampicillin Probenate; Polymyxin B Sulfate; Porfiromycin; Propikacin; Pyrazinamide; Pyrithione Zinc; Quindecamine Acetate; Quinupristin; Racephenicol; Ramoplanin; Ranimycin; Relomycin; Repromicin; Rifabutin; Rifametane; Rifamexil; Rifamide; Rifampin; Rifapentine; Rifaximin; Rolitetracycline; Rolitetracycline Nitrate; Rosaramicin; Rosaramicin Butyrate; Rosaramicin Propionate; Rosaramicin Sodium Phosphate; Rosaramicin Stearate; Rosoxacil; Roxarsone; Roxithromycin; Sancycline; Sanfetrinem Sodium; Sarmoxicillin; Sarpicillin; Scopafungin; Sisomicin; Sisomicin Sulfate; Sparfloxacin; Spectinomycin Hydrochloride; Spiramycin; Stallimycin Hydrochloride; Steffimycin; Streptomycin Sulfate; Streptonicozid; Sulfabenz: Sulfabenzamide; Sulfacetamide; Sulfacetamide Sodium; Sulfacytine; Sulfadiazine; Sulfadiazine Sodium; Sulfadoxine; Sulfalene; Sulfamerazine; Sulfameter; Sulfamethazine; Sulfamethizole; Sulfamethoxazole; Sulfamonomethoxine; Sulfamoxole; Sulfanilate Zinc; Sulfanitran; Sulfasalazine; Sulfasomizole; Sulfathiazole; Sulfazamet; Sulfisoxazole; Sulfisoxazole Acetyl; Sulfisoxazole Diolamine; Sulfomyxin; Sulopenem; Sultamicillin; Suncillin Sodium; Talampicillin Hydrochloride; Teicoplanin; Temafloxacin Hydrochloride; Temocillin; Tetracycline; Tetracycline Hydrochloridc; Tetracycline Phosphate Complex; Tetroxoprim; Thiamphenicol; Thiphencillin Potassium; Ticarcillin Cresyl Sodium; Ticarcillin Disodium; Ticarcillin Monosodium; Ticlatone; Tiodonium Chloride; Tobramycin; Tobramycin Sulfate; Tosufloxacin; Trimethoprim; Trimethoprim Sulfate; Trisulfapyrimidines; Troleandomycin; Trospectomycin Sulfate; Tyrothricin; Vancomycin; Vancomycin<!-- EPO <DP n="32"> --> Hydrochloride; Virginiamycin; Zorbamycin; Difloxacin Hydrochloride; Lauryl Isoquinolinium Bromide; Moxalactam Disodium; Omidazole; Pentisomicin; and Sarafloxacin Hydrochloride.</p><p id="p0063" num="0063">Exemplary anti-cancer agents include Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexatc; Eflorithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epipropidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta-I a; Interferon Gamma-I b; Iproplatini; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine; Meturedepa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate; Perfosfamide;<!-- EPO <DP n="33"> --> Pipobroman; Piposulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Podofilox; Porfimer Sodium; Porfiromycin; Prednimustine; Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol; Safingol Hydrochloride; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Sulofenur; Talisomycin; Taxotere; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil Mustard; Uredepa; Vapreotide; Verteporlin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate Virlrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; and Zorubicin Hydrochloride.</p><p id="p0064" num="0064">Exemplary immunosuppressants include Azathioprine; Azathioprine Sodium; Cyclosporine; Daltroban; Gusperimus Trihydrochloride; Sirolimus; and Tacrolimus. Exemplary anti-inflammatory agents include Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium; Diclofenac Sodium; Diflorasone Diacetate; Diflumidone Sodium; Diflunisal; Difluprednate; Diftalone; Dimethyl Sulfoxide; Drocinonide; Endrysone; Enlimomab; Enolicam Sodium; Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen; Fenclofenac; Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid; Flumizole; Flunisolide Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propionate; Furaprofen; Furobufen;<!-- EPO <DP n="34"> --> Halcinonide; Halobetasol Propionate; Halopredone Acetate; Ibufenac; Ibuprofen; lbuprofen Aluminum; lbuprofen Piconol; Ilonidap; Indomethacin; Indomethacin Sodium; Indoprofen; Indoxole; Intrazole; Isoflupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole Hydrochloride; Lornoxicam; Loteprednol Etabonate; Meclofenamate Sodium; Meclofenamic Acid; Meclorisone Dibutyrate; Mefenamic Acid; Mesalamine; Meseclazone; Methylprednisolone Suleptanate; Morniflumate; Nabumetone; Naproxen; Naproxen Sodium; Naproxol; Nimazone; Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride; Pentosan Polysulfate Sodium; Phenbutazone Sodium Glycerate; Pirfenidone; Piroxicam; Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednazate; Prifelone; Prodolic Acid; Proquazone; Proxazole; Proxazole Citrate; Rimexolone; Romazarit; Salcolex; Salnacedin; Salsalate; Sanguinarium Chloride; Seclazone; Sermetacin; Sudoxicam; Sulindac; Suprofen; Talmetacin; Talniflumate; Talosalate; Tebufelone; Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine; Tiopinac; Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate; Zidometacin; and Zomepirac Sodium.</p><p id="p0065" num="0065">As used herein, "treatment" and/or "treating" refer to therapeutic treatment as well as prophylactic treatment or preventative measures. The chemorepellant and/or other therapeutic (such as an antibody to the chemorepellant) can be administered in pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient. The excipient can be chosen based on the expected route of administration of the composition in therapeutic applications. The route of administration of the composition depends on the condition to be treated. Routes of administration include, but are not limited to, parenteral, topic, oral, intramuscular, intravenous administration. The route of administration and the dosage of the composition to be administered can be determined by the skilled artisan without undue experimentation in conjunction with standard dose-response studies. Relevant circumstances to be considered in making those determinations include the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms. In one embodiment, the chemorepellant or a composition thereof is administered locally.<!-- EPO <DP n="35"> --></p><p id="p0066" num="0066">The therapeutic compositions used in the inventive methods can be administered parenterally such as, for example, by intravenous, intramuscular, intrathecal, or subcutaneous injection. Parenteral administration can be accomplished by incorporating the therapeutic compositions of the present invention into a solution or suspension. Such solutions or suspensions may also include sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, or other synthetic solvents. Parenteral formulations may also include antibacterial agents such as, for example, benzyl alcohol or methyl parabens, antioxidants such as, for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA. Buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added. The parenteral preparation can be enclosed in ampules, disposable syringes, or multiple dose vials made of glass or plastic.</p><p id="p0067" num="0067">The invention is illustrated by the following examples which are not meant to be limiting in any way.</p><heading id="h0006">EXEMPLIFICATION</heading><heading id="h0007"><u>EXAMPLE 1: Identification of modulators of cell migration present in tumor environments</u></heading><p id="p0068" num="0068">Objective: To identify the agents present in tumor microenvironments that have the ability to modulate the migration of immune cell subsets.</p><heading id="h0008">Materials and Methods:</heading><p id="p0069" num="0069">Cystic fluid samples: Fluids from ovarian carcinoma patients were collected during surgical procedures under a signed informed consent. Fluids were centrifuged to remove the debris. The supernatants were supplemented with cocktail of protease inhibitors and divided into aliquots and stored at -80C till further processing. Samples were evaluated to study their effects on migration of neutrophils in transwell migration assays in Boyden chambers for their chemoattraction (CA) and chemorepulsion (CR) activities as described below.<!-- EPO <DP n="36"> --></p><p id="p0070" num="0070">Chromatographic separation: Cystic fluid (0.2 ml at 65 mg/ml) was loaded on a Superdex 200 10/300 GL column (GE Healthcare) and fractionated at the rate of 0.5 ml/min. Fractions (1 ml) were collected in tubes preloaded with 10 µl of 100X concentration Complete EDTA-free Protease Inhibitor Cocktail (Roche). These fractions were evaluated for CA CR activities in transwell migration assays described below.</p><p id="p0071" num="0071">One and two dimensional SDS-PAGE analysis: Fractions collected from S-200 chromatography with CR activity and the adjacent fractions without CR activity were further fractionated by one and two dimensional SDS-PAGE. Proteins band and/or spots differentially present in S-200 fractions with CR activity were excised manually, digested with trypsin, and subjected to either LC-MS/MS (1-D bands) or MALDI (2-D spots) analysis.</p><p id="p0072" num="0072">The chemorepulsive activity of the cystic fluid, fractions collected from S-200 chromatography and the proteins listed below was determined as follows:</p><p id="p0073" num="0073">Prior to beginning the assay, the following were prepared:
<ul><li>0.5% Fetal Calf Serum (FCS) in Iscove's Modified Dulbecco's Medium (IMDM) (Assay Medium) (Both from ATCC).</li><li>Migratory cells at a concentration of 2x10<sup>7</sup> cells/ml in Assay Medium.</li><li>Four serial (3-fold) dilutions of the ligand of interest in Assay Medium.</li></ul></p><p id="p0074" num="0074">The assay plates are Neuroprobe ChemoTx plates, part number 206-3 (3um pore size) for neutrophils.
<ul><li>31 µl of the following solutions were pipetted into each well:</li><li>For media controls and for chemorepulsion samples, Assay Medium was used.</li><li>For chemoattraction samples, appropriate dilution of ligand was used.</li></ul></p><p id="p0075" num="0075">The membrane was carefully placed onto the plate, starting at one side and then slowly lowering the other edge onto the plate.
<ul><li>29 µl of the following were pipetted onto the top of each circle:</li><li>For media controls and chemoattraction samples, use Assay Medium.</li><li>For chemorepulsion samples, use the appropriate dilution of ligand.</li><li>2 µl of cells (40,000 cells) were added to each bubble of liquid from step 7.</li></ul><!-- EPO <DP n="37"> -->
<img id="ib0025" file="imgb0025.tif" wi="109" he="35" img-content="undefined" img-format="tif"/></p><p id="p0076" num="0076">The plate was covered with the supplied lid and incubated for the desired time at 37 °C in 5% CO<sub>2</sub>. Unless otherwise indicated, the incubation time was 1 hour for neutrophils and 3 hours for T cells. For monocytes and B cells, the incubation time was 2 hours.</p><p id="p0077" num="0077">After the desired assay time, the liquid was removed from the top of the plate using a Kimwipe.</p><p id="p0078" num="0078">The membrane was carefully removed from the top of the plate and discarded. The plate was examined under a microscope to look for ligand crystallization, contamination and overall migration.</p><p id="p0079" num="0079">White read plates were preloaded with 25ul PBS.</p><p id="p0080" num="0080">Using a multichannel pipettor, 5ul of Cell Titer Glo (Promega # G7572) was added to each well.</p><p id="p0081" num="0081">Using a multichannel pipettor set at 30ul, lysed cell solution was transferred to white read plates pre-loaded with PBS.</p><p id="p0082" num="0082">The plate was read using the BioTek Synergy4 plate reader in order to quantify the number of migrated cells.</p><heading id="h0009">Results:</heading><p id="p0083" num="0083">From mass spectrometry (MS) analysis, 86 proteins in the chemorepulsion active chromatography fraction have been identified which are represented in the following table.<!-- EPO <DP n="38"> -->
<tables id="tabl0001" num="0001"><table frame="all"><title>Table 1: Proteins present in specific active fragments of S200</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="125mm"/><colspec colnum="2" colname="col2" colwidth="41mm"/><thead><row><entry valign="top"><b>Identified Proteins</b></entry><entry valign="top"><b>Accession Number</b></entry></row></thead><tbody><row><entry>A1BG Alpha-1B-glycoprotein precursor</entry><entry>IPI00022895</entry></row><row><entry>A2M Alpha-2-macroglobulin precursor</entry><entry>IPI00478003</entry></row><row><entry>ACTA2 Actin, aortic smooth muscle</entry><entry>IPI00008603 (+9)</entry></row><row><entry>ACTB Actin, cytoplasmic 1</entry><entry>IPI00021439 (+2)</entry></row><row><entry>AFM Afamin precursor</entry><entry>IPI00019943</entry></row><row><entry>AHSG Alpha-2-HS-glycoprotein precursor</entry><entry>IPI00022431 (+1)</entry></row><row><entry>ALB Isoform 1 of Serum albumin precursor</entry><entry>IPI00745872 (+1)</entry></row><row><entry>Alpha 2 HS-glycoprotein</entry><entry>P02765; gi:112910</entry></row><row><entry>ANPEP Aminopeptidase N</entry><entry>IPI00221224</entry></row><row><entry>APOA1 Apolipoprotein A-I precursor</entry><entry>IPI00021841 (+1)</entry></row><row><entry>apolipoprotein A-1</entry><entry>P02647</entry></row><row><entry>apolipoprotein A-IV</entry><entry>P06727</entry></row><row><entry>C1RL Complement C1r subcomponent-like protein precursor</entry><entry>IPI00009793 (+2)</entry></row><row><entry>C2 Complement C2 precursor (Fragment)</entry><entry>IPI00303963</entry></row><row><entry>C3 Complement C3 precursor (Fragment)</entry><entry>IPI00783987</entry></row><row><entry>C4A Complement component 4A</entry><entry>IPI00643525</entry></row><row><entry>C9 Complement component C9 precursor</entry><entry>IPI00022395</entry></row><row><entry>carbonic anhydrase 1</entry><entry>P00915</entry></row><row><entry>CD163 Isoform 1 of Scavenger receptor cysteine-rich type 1 protein M130 precursor</entry><entry>IPI00104074 (+3)</entry></row><row><entry>CFB Isoform 1 of Complement factor B precursor (Fragment)</entry><entry>IPI00019591</entry></row><row><entry>CP Ceruloplasmin precursor</entry><entry>IPI00017601</entry></row><row><entry>EEF1A2 Elongation factor 1-alpha 2</entry><entry>IPI00014424 (+3)</entry></row><row><entry>F2 Prothrombin precursor (Fragment)</entry><entry>IPI00019568</entry></row><row><entry>GC Vitamin D-binding protein precursor</entry><entry>IPI00555812 (+1)</entry></row><row><entry>GSN Isoform 1 of Gelsolin precursor</entry><entry>IPI00026314 (+1)</entry></row><row><entry>H2AFV Histone H2AV</entry><entry>IPI00018278 (+15)</entry></row><row><entry>HABP2 Hyaluronan-binding protein 2 precursor</entry><entry>IPI00746623</entry></row><row><entry>HBA2;HBA1 Hemoglobin subunit alpha</entry><entry>IPI00410714 (+1)</entry></row><!-- EPO <DP n="39"> --><row><entry>HBB Hemoglobin subunit beta</entry><entry>IPI00654755 (+1)</entry></row><row><entry>hemoglobin beta</entry><entry>P68871</entry></row><row><entry>hemopexin</entry><entry>P02790</entry></row><row><entry>HIST1H1D Histone H1.3</entry><entry>IPI00217466 (+2)</entry></row><row><entry>HIST1H2AM;HIST1H2AG;HIST1H 2AJ;HIST1H2AL;HIST1H2AK;HIS T1H2AI Histone H2A type 1</entry><entry>IPI00291764 (+9)</entry></row><row><entry>HIST2H3A;HIST2H3C;HIST2H3 D Histone H3.2</entry><entry>IPI00171611 (+7)</entry></row><row><entry>HIST2H4A;HIST1H4C;HIST1H4 A;HIST1 H41;HIST1 H4E;HIST1 H4 F;HIST1 H4K;HIST1 H4H;HIST4H 4;HIST1 H4L;HIST1 H4D;HIST1 H 4J;HIST2H4B;HIST1 H4B Histone H4</entry><entry>IPI00453473</entry></row><row><entry>HPX Hemopexin precursor</entry><entry>IPI00022488</entry></row><row><entry>HRG Histidine-rich glycoprotein precursor</entry><entry>IPI00022371</entry></row><row><entry>HRNR Hornerin</entry><entry>IPI00398625 (+2)</entry></row><row><entry>IGFALS Insulin-like growth factor-binding protein complex acid labile chain precursor</entry><entry>IPI00020996</entry></row><row><entry>IGHD IGHD protein</entry><entry>IPI00418422 (+2)</entry></row><row><entry>IGHG1 IGHG1 protein</entry><entry>IPI00448925</entry></row><row><entry>IGHG1 IGHG1 protein</entry><entry>IPI00815926</entry></row><row><entry>IGHG3 IGHG3 protein</entry><entry>IPI00472345</entry></row><row><entry>IGHM;IGH@ IGHM protein</entry><entry>IPI00472610</entry></row><row><entry>IGHV1OR15-1 Ig heavy chain V-I region V35 precursor</entry><entry>IPI00009792</entry></row><row><entry>IGHV3OR16-13;IGHA1 IGHA1 protein</entry><entry>IPI00061977</entry></row><row><entry>IGHV3OR16-13;IGHA1 IGHA1 protein</entry><entry>IPI00430842</entry></row><row><entry>IGHV4-31 IGHV4-31 protein</entry><entry>IPI00784822</entry></row><row><entry>IGKV1-5 IGKV1-5 protein</entry><entry>IPI00419424 (+19)</entry></row><row><entry>IGL@ IGL@ protein</entry><entry>IPI00154742</entry></row><row><entry>ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 precursor</entry><entry>IPI00305461 (+1)</entry></row><row><entry>ITIH4 Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H4 precursor</entry><entry>IPI00294193</entry></row><row><entry>ITIH4 Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 precursor</entry><entry>IPI00218192 (+3)</entry></row><row><entry>KNG1 Isoform LMW of Kininogen-1 precursor</entry><entry>IPI00215894 (+1)</entry></row><row><entry>KPRP Keratinocyte proline-rich protein</entry><entry>IPI00514908</entry></row><!-- EPO <DP n="40"> --><row><entry>KRT1 Keratin, type II cytoskeletal 1</entry><entry>IPI00220327 (+1)</entry></row><row><entry>KRT10 Keratin, type I cytoskeletal 10</entry><entry>IPI00009865 (+1)</entry></row><row><entry>KRT14 Keratin, type I cytoskeletal 14</entry><entry>IPI00384444</entry></row><row><entry>KRT16 Keratin, type I cytoskeletal 16</entry><entry>IPI00217963</entry></row><row><entry>KRT2 Keratin, type II cytoskeletal 2 epidermal</entry><entry>IPI00021304 (+1)</entry></row><row><entry>KRT5 Keratin, type II cytoskeletal 5</entry><entry>IPI00009867</entry></row><row><entry>KRT6A Keratin, type II cytoskeletal 6A</entry><entry>IPI00300725</entry></row><row><entry>KRT9 Keratin, type I cytoskeletal 9</entry><entry>IPI00019359 (+1)</entry></row><row><entry>LDHA Isoform 1 of L-lactate dehydrogenase A chain</entry><entry>IPI00217966 (+2)</entry></row><row><entry>LUM Lumican precursor</entry><entry>IPI00020986 (+1)</entry></row><row><entry>LYZ Lysozyme C precursor</entry><entry>IPI00019038 (+1)</entry></row><row><entry>plasma retinol-binding protein</entry><entry>P02753</entry></row><row><entry>SERPINA1 Isoform 1 of Alpha-1-antitrypsin precursor</entry><entry>IPI00553177</entry></row><row><entry>SERPINA3 Alpha-1-antichymotrypsin precursor</entry><entry>IPI00550991 (+1)</entry></row><row><entry>SERPINA7 Thyroxine-binding globulin precursor</entry><entry>IPI00292946</entry></row><row><entry>SERPIND1 Serpin peptidase inhibitor, clade D (Heparin cofactor), member 1</entry><entry>IPI00292950 (+1)</entry></row><row><entry>SERPINF2 SERPINF2 protein</entry><entry>IPI00029863 (+1)</entry></row><row><entry>SLPI Antileukoproteinase precursor</entry><entry>IPI00008580</entry></row><row><entry>sp_ALBU_BOVIN</entry><entry>IPIsp_ALBU_BOVIN</entry></row><row><entry>sp_ANT3_HUMAN</entry><entry>IPIsp_ANT3_HUMAN</entry></row><row><entry>sp_TRYP_PIG</entry><entry>IPIsp_TRYP_PIG</entry></row><row><entry>TF Serotransferrin precursor</entry><entry>IPI00022463 (+2)</entry></row><row><entry>transthyretin</entry><entry>P02766</entry></row><row><entry>Putative uncharacterized protein DKFZp686C15213</entry><entry>IPI00426051</entry></row><row><entry>cDNA FLJ78387</entry><entry>IPI00876888</entry></row><row><entry>Ig heavy chain V-III region CAM</entry><entry>IPI00382482</entry></row><row><entry>Single-chain Fv (Fragment)</entry><entry>IPI00470652</entry></row><row><entry>uncharacterized protein ENSP00000375035</entry><entry>IPI00735451</entry></row><row><entry>uncharacterized protein ENSP00000375026</entry><entry>IPI00829845</entry></row><row><entry>YWHAZ 14-3-3 protein zeta/delta</entry><entry>IPI00021263 (+1)</entry></row><row><entry>zinc-alpha-2-glycoprotein</entry><entry>P25311</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="41"> --></p><p id="p0084" num="0084">Some of these proteins were evaluated individually and in combinations for their effects on CA and CR activity. Of these proteins, actin, 14-3-3 zeta/delta, apolipoprotein A1 and hemopexin showed the greatest CA and/or CR activities. <figref idrefs="f0001 f0002 f0003 f0004 f0005 f0006">Figures 1 through 6</figref> represent the effect of whole cyst fluid, Superdex 200 fractions, Actin and 14-3-3 individually, the same two proteins assayed in combination, Apolipoprotein A1, and hemopexin on migration of human neutrophils in CA and CR modes.</p><heading id="h0010">Legends for the figures:</heading><p id="p0085" num="0085"><ul><li><figref idrefs="f0001">Figure 1</figref>: Effect of Cystic fluid on migration of human neutrophils. Human neutrophils were tested at different concentrations of cyst fluid: neat (undiluted), and at 1:3, 1:10 and 1:30 diluted in media. Both chemoattraction (CA) and chemorepulsion were measured using a Boyden chamber transwell migration assay. Cystic fluid has efficiently repelled human neutrophils as studied by transwell migration assays at all concentrations tested.</li><li><figref idrefs="f0002">Figure 2</figref>: Evaluation of S-200 chromatography fractionation of cystic fluids on human neutrophils in transwell migration assay. Fractions were evaluated for chemoattraction (CA) and chemorepulsion of human neutrophils using a Boyden chamber transwell migration assay. Fractions A15 and B1 have the highest neutrophil repulsive activities as compared to other fractions.</li><li><figref idrefs="f0003">Figure 3</figref>: Effect of human actin and 14-3-3 on migration of human neutrophils. Actin and 14-3-3 were evaluated at different concentrations for their abilities to induce chemorepulsion (CR) of human neutrophils using a Boyden chamber transwell migration assay. Human neutrophils were effectively repelled by actin in transwell migration assays.</li><li><figref idrefs="f0004">Figure 4</figref>: Effect of 1:1 combination of Actin and 14-3-3 on migration of human neutrophils. Actin and 14-3-3 were evaluated in 1:1 combination at different concentrations for their ability to induce chemoattraction (CA) and chemorepulsion (CR) of human neutrophils using a Boyden chamber transwell migration assay. Actin and 14-3-3 in combination effectively modulated human neutrophil migrations in transwell migration assays.<!-- EPO <DP n="42"> --></li><li><figref idrefs="f0005">Figure 5</figref>: Effect of apolipoprotein A1 on migration of human neutrophils. Apolipoprotein A1 was evaluated at different concentrations for its ability to induce chemoattraction (CA) and chemorepulsion (CR) of human neutrophils using a Boyden chamber transwell migration assay. Human neutrophils were effectively repelled by apolipoprotein A1 at 5.1 microM concentration.</li><li><figref idrefs="f0006">Figure 6</figref>: Effect of hemopexin on migration of human neutrophils. Hemopexin was evaluated at different concentrations for its ability to induce chemoattraction (CA) and chemorepulsion (CR) of human neutrophils using a Boyden chamber transwell migration assay. Human neutrophils were effectively attracted at 8.8 microM concentration of hemopexin.</li></ul></p><heading id="h0011"><u>Example 2: Identification of modulators of cell migration present in mammalian cancer cell line supernatants</u></heading><p id="p0086" num="0086">Objective: To identify the agents present in mammalian cancer cell lines that have the ability to modulate the migration of immune cell subsets.</p><heading id="h0012">Materials and Methods:</heading><heading id="h0013">Mammalian cancer cell lines:</heading><p id="p0087" num="0087">Cancer cell lines were cultured in serum containing media until desired confluence is reached. Culture conditions were switched to serum-free media and supernatants collected everyday up to certain number of days. The supernatants were supplemented with cocktail of protease inhibitors and divided into aliquots and stored at -80C until further processing. Depending on the volume of culture supernatant, they were either concentrated 10 times or evaluated unconcentrated to study their effects on neutrophil migration Boyden chamber transwell migration assays.</p><heading id="h0014">Chromatographic separation:</heading><p id="p0088" num="0088">Supernatants were further concentrated and loaded on a Superdex 200 10/300 GL column (GE Healthcare) and fractionated at the rate of 0.5 ml/min. Fractions (1 ml) were collected in tubes preloaded with 10 ul of 100X concentration Complete EDTA-free Protease Inhibitor Cocktail (Roche). These fractions were<!-- EPO <DP n="43"> --> evaluated for chemoattraction (CA) and chemorepulsion (CR) activities in transwell migration assays described below.</p><p id="p0089" num="0089">Supernatants for the breast cancer cell line, SK-BR-3 were first dialyzed overnight and then loaded on a HiTrap-Q Fast Flow anion exchange column and fractionated at a rate of 1mL/min. 3mL fractions were desalted and evaluated for chemoattraction (CA) and chemorepulsion (CR) activities in transwell migration assays as described below.</p><heading id="h0015">One dimensional SDS-PAGE analysis:</heading><p id="p0090" num="0090">Fractions collected from S-200 and anion exchange chromatography with CR activity and the adjacent fractions without CR activity were further fractionated by one dimensional SDS-PAGE. Proteins bands differentially present in S-200 fractions with CR activity were excised manually, digested with trypsin, and subjected to LC-MS/MS.</p><p id="p0091" num="0091">The chemorepulsive activity of the supernatants, fractions collected from S-200 and anion exchange chromatography and the proteins listed below were determined as follows:</p><heading id="h0016">Transwell migration Assay:</heading><p id="p0092" num="0092"><ol><li>1. Prior to beginning the assay, the following were prepared:
<ol><li>a. 0.5% Fetal Calf Serum (FCS) in Iscove's Modified Dulbecco's Medium (IMDM) (Assay Medium) (Both from ATCC).</li><li>b. Migratory cells at a concentration of 2x10<sub>7</sub> cells/ml in Assay Medium.</li></ol></li><li>2. The assay plates are Neuroprobe ChemoTx plates, part number 206-3 (3um pore size) for neutrophils.</li><li>3. 31 µl of the following solutions were pipetted into each well:
<ol><li>a. For media controls and for chemorepulsion samples, Assay Medium was used.</li><li>b. For chemoattraction samples, appropriate dilution of ligand was used.</li></ol></li><li>4. The membrane was carefully placed onto the plate, starting at one side and then slowly lowering the other edge onto the plate.</li><li>5. 29 µl of the following were pipetted onto the top of each circle:
<ol><li>a. For media controls and chemoattraction samples, Assay Medium was used.</li><li>b. For chemorepulsion samples, the appropriate dilution of ligand was used.</li></ol></li><li>6. 2 µl of cells (40,000 cells) were added to each bubble of liquid from step 7.<!-- EPO <DP n="44"> --></li><li>7. The plate was covered with the supplied lid and incubated for 1 hour at 37 °C in 5% CO<sub>2</sub>.</li><li>8. The liquid was then removed from the top of the plate using a Kimwipe.</li><li>9. The plate was then examined under a microscope to look for crystallization, contamination and overall migration.</li></ol></p><p id="p0093" num="0093">From this point assay plates were either processed by method A: CTG (Cell Titer Glo via relative luminescence units for read out) or method B: Guava (via cell count for read out).</p><heading id="h0017">Method A:</heading><p id="p0094" num="0094"><ol><li>1. White read plates were preloaded with 25ul PBS and 5ul of Cell Titer Glo (Promega # G7572) was added to each well of the transmigration plate.</li><li>2. Using a multichannel pipettor set at 30ul, lysed cell solution was transferred to white read plates pre-loaded with PBS.</li><li>3. The plate was read using the BioTek Synergy4 plate reader in order to quantify the number of migrated cells.</li></ol></p><heading id="h0018">Method B:</heading><p id="p0095" num="0095">U-bottom 96 well plates were preloaded with 50ul assay media and the contents of the Neuroprobe plates were transferred to the U-bottom plate.</p><p id="p0096" num="0096">Equal volumes of Guava viacount reagent was added to each well to stain the cells. The plate was then incubated for 5 minutes in the dark at room temperature.</p><p id="p0097" num="0097">1% paraformaldehyde was added to fix the cells and they were then sealed with adhesive film and stored at 4 °C overnight.</p><p id="p0098" num="0098">The Guava Easy Cyte Plus was used to read the plate and quantify the number of migrated cells.</p><p id="p0099" num="0099">Bands from supernatant fractions that exhibited chemorepulsive activity were sent out for MS (Liquid chromatography/Mass Spectrometry/Mass Spectrometry) analysis (outsourced). Commercially available proteins corresponding to proteins identified in Mass Spectrometry were then tested in cell migration assay.<!-- EPO <DP n="45"> --></p><p id="p0100" num="0100">Protein identification was performed by outside sources using nano LC/MS/MS (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry) on an LTQ ("linear trap quadrupole") mass spectrometer. Protein samples were submitted in a gel or solution and were first digested robotically using trypsin to create a peptide mixture (alternate enzymes may be employed if necessary). Peptides were then injected on a custom-designed LC column set-up and eluted into the mass spectrometer where MS and MS/MS were performed. Product ion data was searched using forward and reversed database searching methods to allow assessment of false discovery rates and ensure only correct protein identifications were reported. Search results were parsed into the Scaffold™ visualization software to allow further validation of protein assignments through the ProteinProphet™ and PeptideProphet™<sup>1</sup> tools.</p><p id="p0101" num="0101">The methods used for In-gel digestion are as below:</p><p id="p0102" num="0102">Samples were subjected to proteolytic digestion on a ProGest workstation as follows:</p><p id="p0103" num="0103">The samples were reduced with DTT at 60°C, allowed to cool to room temperature, alkylated with iodoacetamide, incubated at 37°C for 4h in the presence trypsin and formic acid was added to stop the reaction.</p><p id="p0104" num="0104">The method used for Mass Spectrometry - Solution Based are below:</p><p id="p0105" num="0105">Samples were subjected to C18 capture using ZipTips. They were aspirated across equilibrated C18 ZipTip, washed in 0.1% formic acid, eluted in 80% acetonitrile in 0.1% formic acid, concentrated by vacuum centrifugation and resuspended in 0.1% formic acid for injection.</p><p id="p0106" num="0106">The methods used for LC/MS/MS (data-dependent) are as below:</p><p id="p0107" num="0107">Samples were analyzed by nano LC/MS/MS on a ThermoFisher LTQ XL or Orbitrap XL. 30µl of hydrolysate were loaded on a 75µm C12 vented column at a flow-rate of 10µL/minand eluted at 300nL/min and a 1h gradient was employed. MS/MS data were searched using a local copy of Mascot <u>(www.matrixscience.com)</u> The parameters for all LC/MS/MS (Mascot) searches were as follows:
<ul><li>Type of search: MS/MS Ion Search</li><li>Enzyme: Trypsin</li><li>Fixed modifications: Carbamidomethyl (C)<!-- EPO <DP n="46"> --></li><li>Variable modifications Oxidation (M, Acetyl (N-term, Pyro-glu (N-term Q)</li><li>Mass values: Monoisotopic</li><li>Protein Mass: Unrestricted</li><li>Peptide Mass Tolerance: ± 10 ppm (Orbitrap); ± 2.0 Da (LTQ)</li><li>Fragment Mass Tolerance: ± 0 5 Da (LTQ)</li><li>Max Missed Cleavages: 1</li></ul></p><p id="p0108" num="0108">Samples were processed in the Scaffold™ Algorithm <u>(www.proteomesoftware.com)</u> using .DAT files generated by MASCOT™. Parameters for LTQ data require a minimum of 3 peptides matching per protein with minimum probabilities of 95% at the protein level and 50- 80% at the corresponding peptide level. QTOF/Orbitrap data require a minimum of 2 peptides with the same minimum probability thresholds due to the superior mass accuracy of that instrument.</p><p id="p0109" num="0109">NOTE: Detailed protocols for each of these methods can be found in the technical information section of <u>http://www.prsproteomics.com.</u></p><p id="p0110" num="0110">NOTE: SK-BR-3 was outsourced using LC/MS/MS performed at University of Georgia, Proteomics Resource Facility.</p><heading id="h0019">Results:</heading><p id="p0111" num="0111">The chemorepulsive activity of supernatants, fractions collected from chromatography and commercially available proteins are shown in <figref idrefs="f0007 f0008 f0009 f0010 f0011 f0012 f0013 f0014 f0015 f0016 f0017 f0018 f0019 f0020 f0021 f0022 f0023 f0024 f0025 f0026 f0027 f0028 f0029 f0030 f0031 f0032 f0033 f0034 f0035 f0036 f0037 f0038 f0039">FIGs. 7-39</figref>.</p><p id="p0112" num="0112">Proteins identified in the chemorepulsive supernatant fractions by LC/MS/MS (mass spectrometry) are shown in the Tables below:
<tables id="tabl0002" num="0002"><table frame="all"><title>Table 2: Proteins identified by MS in Renal Cell Lines ACHN and 786-O</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="118mm"/><colspec colnum="2" colname="col2" colwidth="48mm"/><thead><row><entry align="center" valign="middle"><b>Protein:</b></entry><entry align="center" valign="middle"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center" valign="middle">ACBD3 Golgi resident protein GCP60</entry><entry align="center" valign="middle">IPI00009315</entry></row><row><entry align="center" valign="middle">ADPRHL2 Poly(ADP-ribose) glycohydrolase ARH3</entry><entry align="center" valign="middle">IPI00015865</entry></row><row><entry align="center" valign="middle">AK2 Isoform 1 of Adenylate kinase isoenzyme 2, mitochondrial</entry><entry align="center" valign="middle">IPI00215901 (+1)</entry></row><row><entry align="center" valign="middle">AKR1A1 Alcohol dehydrogenase</entry><entry align="center" valign="middle">IPI00220271</entry></row><row><entry align="center" valign="middle">AKR1B1 Aldose reductase</entry><entry align="center" valign="middle">IPI00413641</entry></row><row><entry align="center" valign="middle">AKR1B10 Aldo-keto reductase family 1 member B10</entry><entry align="center" valign="middle">IPI00105407</entry></row><row><entry align="center" valign="middle">AKR1C1 Aldo-keto reductase family 1 member C1</entry><entry align="center" valign="middle">IPI00029733</entry></row><row><entry align="center" valign="middle">AKR1C2 Aldo-keto reductase family 1 member C2</entry><entry align="center" valign="middle">IPI00005668</entry></row><row><entry align="center" valign="middle">AKR1C3 Aldo-keto reductase family 1 member C3</entry><entry align="center" valign="middle">IPI00291483 (+1)</entry></row><!-- EPO <DP n="47"> --><row><entry align="center" valign="middle">ANP32B Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32 family member B</entry><entry align="center" valign="middle">IPI00007423 (+1)</entry></row><row><entry align="center" valign="middle">ANXA1 Annexin A1</entry><entry align="center" valign="middle">IPI00218918</entry></row><row><entry align="center" valign="middle">ANXA2 Annexin A2</entry><entry align="center" valign="middle">IPI00455315</entry></row><row><entry align="center" valign="middle">APEX1 DNA-(apurinic or apyrimidinic site) lyase</entry><entry align="center" valign="middle">IPI00215911</entry></row><row><entry align="center" valign="middle">APOA1BP Isoform 1 of Apolipoprotein A-I-binding protein precursor</entry><entry align="center" valign="middle">IPI00168479 (+1)</entry></row><row><entry align="center" valign="middle">ARHGDIA Rho GDP-dissociation inhibitor 1</entry><entry align="center" valign="middle">IPI00003815 (+1)</entry></row><row><entry align="center" valign="middle">ARMET Protein ARMET precursor</entry><entry align="center" valign="middle">IPI00328748</entry></row><row><entry align="center" valign="middle">ASF1A Histone chaperone ASF1A</entry><entry align="center" valign="middle">IPI00292168</entry></row><row><entry align="center" valign="middle">BSG Isoform 2 of Basigin precursor</entry><entry align="center" valign="middle">IPI00019906 (+1)</entry></row><row><entry align="center" valign="middle">C11orf54 Isoform 3 of Ester hydrolase C11orf54</entry><entry align="center" valign="middle">IPI00061507 (+2)</entry></row><row><entry align="center" valign="middle">C19orf33 Isoform 1 of Immortalization up-regulated protein</entry><entry align="center" valign="middle">IPI00030767</entry></row><row><entry align="center" valign="middle">Clorf128 Isoform 1 of UPF0424 protein Clorf128</entry><entry align="center" valign="middle">IPI00015351</entry></row><row><entry align="center" valign="middle">C7orf24 Uncharacterized protein C7orf24</entry><entry align="center" valign="middle">IPI00031564</entry></row><row><entry align="center" valign="middle">CA12 Isoform 1 of Carbonic anhydrase 12 precursor</entry><entry align="center" valign="middle">IPI00012895 (+1)</entry></row><row><entry align="center" valign="middle">CA2 Carbonic anhydrase 2</entry><entry align="center" valign="middle">IPI00218414 (+1)</entry></row><row><entry align="center" valign="middle">CAB39 Calcium-binding protein 39</entry><entry align="center" valign="middle">IP100032561</entry></row><row><entry align="center" valign="middle">CALD1 Isoform 4 of Caldesmon</entry><entry align="center" valign="middle">IPI00218696</entry></row><row><entry align="center" valign="middle">CALM2;CALM1;CALM3 Calmodulin</entry><entry align="center" valign="middle">IPI00075248 (+2)</entry></row><row><entry align="center" valign="middle">CAPG Macrophage-capping protein</entry><entry align="center" valign="middle">IPI00027341 (+1)</entry></row><row><entry align="center" valign="middle">CAPZA2 F-actin-capping protein subunit alpha-2</entry><entry align="center" valign="middle">IPI00026182 (+3)</entry></row><row><entry align="center" valign="middle">CASP3 Caspase-3 precursor</entry><entry align="center" valign="middle">IPI00292140</entry></row><row><entry align="center" valign="middle">CAST Isoform 2 of Calpastatin</entry><entry align="center" valign="middle">IP100220857 (+11)</entry></row><row><entry align="center" valign="middle">CCDC25 Coiled-coil domain-containing protein 25</entry><entry align="center" valign="middle">IPI00396174 (+1)</entry></row><row><entry align="center" valign="middle">CDH13 Cadherin-13 precursor</entry><entry align="center" valign="middle">IPI00024046 (+2)</entry></row><row><entry align="center" valign="middle">CDV3 Isoform 1 of Protein CDV3 homolog</entry><entry align="center" valign="middle">IPI00014197 (+2)</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0003" num="0003"><table frame="all"><title>Table 2 continued: Proteins identified by MS in Renal Cell Lines ACHN and 786-O</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="122mm"/><colspec colnum="2" colname="col2" colwidth="44mm"/><thead><row><entry align="center" valign="middle"><b>Protein:</b></entry><entry align="center" valign="middle"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center" valign="middle">CFL1 Cofilin-1</entry><entry align="center" valign="middle">IPI0C012011</entry></row><row><entry align="center" valign="middle">CFL2 Cofilin-2</entry><entry align="center" valign="middle">IPI00413344</entry></row><row><entry align="center" valign="middle">CHAC2 Cation transport regulator-like protein 2</entry><entry align="center" valign="middle">IPI00103047</entry></row><row><entry align="center" valign="middle">CIAPIN1 Isoform 3 of Anamorsin</entry><entry align="center" valign="middle">IPI00025333 (+1)</entry></row><row><entry align="center" valign="middle">CMBL Carboxymethylenebutenolidase homolog</entry><entry align="center" valign="middle">IPI00383046</entry></row><row><entry align="center" valign="middle">CMPK1 cDNA, FU93091, Homo sapiens UMP-CMP kinase (UMP-CMPK), mRNA</entry><entry align="center" valign="middle">IPI00219953</entry></row><row><entry align="center" valign="middle">CNBP Isoform 1 of Cellular nucleic acid-binding protein</entry><entry align="center" valign="middle">IPI00430812 (+6)</entry></row><row><entry align="center" valign="middle">CNPY2 Isoform 1 of Protein canopy homolog 2 precursor</entry><entry align="center" valign="middle">IPI00443909</entry></row><row><entry align="center" valign="middle">CRK v-crk sarcoma virus CT10 oncogene homolog isoform b</entry><entry align="center" valign="middle">IPI00305469</entry></row><row><entry align="center" valign="middle">CRYZ Quinone oxidoreductase</entry><entry align="center" valign="middle">IPI00000792</entry></row><row><entry align="center" valign="middle">CTSS Cathepsin S precursor</entry><entry align="center" valign="middle">IPI00299150</entry></row><row><entry align="center" valign="middle">CTSZ Cathepsin Z precursor</entry><entry align="center" valign="middle">IPI00002745 (+1)</entry></row><!-- EPO <DP n="48"> --><row><entry align="center" valign="middle">CYR61 CYR61 protein</entry><entry align="center" valign="middle">IPI00006273 (+2)</entry></row><row><entry align="center" valign="middle">DDAH1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1</entry><entry align="center" valign="middle">IPI00220342</entry></row><row><entry align="center" valign="middle">DDX21 Isoform 1 of Nucleolar RNA helicase 2</entry><entry align="center" valign="middle">IPI00015953</entry></row><row><entry align="center" valign="middle">DSTN Destrin</entry><entry align="center" valign="middle">IPI00473014</entry></row><row><entry align="center" valign="middle">DTD1 D-tyrosyl-tRNA(Tyr) deacylase 1</entry><entry align="center" valign="middle">IPI00152692</entry></row><row><entry align="center" valign="middle">DUT Isoform DUT-M of Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial precursor</entry><entry align="center" valign="middle">IPI00013679 (+3)</entry></row><row><entry align="center" valign="middle">EEF1G Elongation factor 1-gamma</entry><entry align="center" valign="middle">IPI00000875 (+1)</entry></row><row><entry align="center" valign="middle">EIF1AY Eukaryotic translation initiation factor 1A, Y-chromosomal</entry><entry align="center" valign="middle">IPI00023004 (+1)</entry></row><row><entry align="center" valign="middle">EIF4B Eukaryotic translation initiation factor 4B</entry><entry align="center" valign="middle">IPI00012079 (+1)</entry></row><row><entry align="center" valign="middle">EIF5A Isoform 2 of Eukaryotic translation initiation factor 5A-1</entry><entry align="center" valign="middle">IPI00376005 (+1)</entry></row><row><entry align="center" valign="middle">EIF6 Eukaryotic translation initiation factor 6</entry><entry align="center" valign="middle">IPI00010105</entry></row><row><entry align="center" valign="middle">ERP29 Endoplasmic reticulum protein ERp29 precursor</entry><entry align="center" valign="middle">IPI00024911</entry></row><row><entry align="center" valign="middle">FAHD1 Isoform 2 of Fumarylacetoacetate hydrolase domain-containing protein 1</entry><entry align="center" valign="middle">IPI00440828 (+2)</entry></row><row><entry align="center" valign="middle">FAM3C Protein FAM3C precursor</entry><entry align="center" valign="middle">IPI00334282</entry></row><row><entry align="center" valign="middle">FER1L3 Isoform 1 of Myoferlin</entry><entry align="center" valign="middle">IPI00021048 (+5)</entry></row><row><entry align="center" valign="middle">FLNA filamin A, alpha isoform 1</entry><entry align="center" valign="middle">IPI00302592 (+3)</entry></row><row><entry align="center" valign="middle">FLNC Isoform 1 of Filamin-C</entry><entry align="center" valign="middle">IPI00178352 (+1)</entry></row><row><entry align="center" valign="middle">GL01 Lactoylglutathione lyase</entry><entry align="center" valign="middle">IPI00220766</entry></row><row><entry align="center" valign="middle">GRB2 Isoform 1 of Growth factor receptor-bound protein 2</entry><entry align="center" valign="middle">IPI00021327 (+1)</entry></row><row><entry align="center" valign="middle">GSTM3 Glutathione S-transferase Mu 3</entry><entry align="center" valign="middle">IPI00246975</entry></row><row><entry align="center" valign="middle">GSTP1 Glutathione S-transferase P</entry><entry align="center" valign="middle">IPI00219757 (+1)</entry></row><row><entry align="center" valign="middle">GUK1 Guanylate kinase</entry><entry align="center" valign="middle">IPI00182293 (+3)</entry></row><row><entry align="center" valign="middle">HDDC2 Isoform 2 of HD domain-containing protein 2</entry><entry align="center" valign="middle">IPI00386751 (+1)</entry></row><row><entry align="center" valign="middle">HDGF Hepatoma-derived growth factor</entry><entry align="center" valign="middle">IPI00020956</entry></row><row><entry align="center" valign="middle">HDHD1A Haloacid dehalogenase-like hydrolase domain containing protein</entry><entry align="center" valign="middle">IPI00302436</entry></row><row><entry align="center" valign="middle">HDHD3 Haloacid dehalogenase-like hydrolase domain-containing protein 3</entry><entry align="center" valign="middle">IPI00009931</entry></row><row><entry align="center" valign="middle">HLA-B; HLA-A; HLA-C;LOC441528;XXbac-BPG181B23.1;LOC728687;MICA;LOC100133382 HLA class I histocompatibility antigen, B-42 alpha chain precursor</entry><entry align="center" valign="middle">IPI00472676 (+2)</entry></row><row><entry align="center" valign="middle">HMGA1 Isoform HMG-I of High mobility group protein HMG-I/HMG-Y</entry><entry align="center" valign="middle">IPI00179700</entry></row><row><entry align="center" valign="middle">HMGB3 High mobility group protein B3</entry><entry align="center" valign="middle">IPI00217477 (+2)</entry></row><row><entry align="center" valign="middle">HMGN1 Non-histone chromosomal protein HMG-14</entry><entry align="center" valign="middle">IPI00554761</entry></row><row><entry align="center" valign="middle">HN1 Isoform 1 of Hematological and neurological expressed 1 protein</entry><entry align="center" valign="middle">IPI00007764 (+1)</entry></row><row><entry align="center" valign="middle">HNRNPA2B1 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1</entry><entry align="center" valign="middle">IPI00396378</entry></row><row><entry align="center" valign="middle">HPRT1 Hypoxanthine-guanine phosphoribosyltransferase</entry><entry align="center" valign="middle">IPI00218493</entry></row><row><entry align="center" valign="middle">IAH1 Isoamyl acetate-hydrolyzing esterase 1 homolog</entry><entry align="center" valign="middle">IPI00419194 (+1)</entry></row><row><entry align="center" valign="middle">IGFBP7 Insulin-like growth factor-binding protein 7 precursor</entry><entry align="center" valign="middle">IPI00016915</entry></row><!-- EPO <DP n="49"> --><row><entry align="center" valign="middle">IGSF8 Isoform 1 of Immunoglobulin superfamily member 8 precursor</entry><entry align="center" valign="middle">IPI00056478 (+1)</entry></row><row><entry align="center" valign="middle">IL6 Interleukin-6 precursor</entry><entry align="center" valign="middle">IPI00007793 (+2)</entry></row><row><entry align="center" valign="middle">ITIH5 inter-alpha trypsin inhibitor heavy chain precursor 5 isoform 1</entry><entry align="center" valign="middle">IPI00328829 (+1)</entry></row><row><entry align="center" valign="middle">KIAA0174 Isoform 1 of Uncharacterized protein KIAA0174</entry><entry align="center" valign="middle">IPI00024660 (+2)</entry></row><row><entry align="center" valign="middle">LASP1 Isoform 1 of LIM and SH3 domain protein 1</entry><entry align="center" valign="middle">IPI00000861 (+2)</entry></row><row><entry align="center" valign="middle">LDHB L-lactate dehydrogenase B chain</entry><entry align="center" valign="middle">IPI00219217</entry></row><row><entry align="center" valign="middle">LMAN2 Vesicular integral-membrane protein VIP36 precursor</entry><entry align="center" valign="middle">IPI00009950</entry></row><row><entry align="center" valign="middle">LMNA Isoform A of Lamin-A/C</entry><entry align="center" valign="middle">IPI00021405 (+4)</entry></row><row><entry align="center" valign="middle">LMNB1 Lamin-B1</entry><entry align="center" valign="middle">IPI00217975</entry></row><row><entry align="center" valign="middle">LMNB2 Lamin-B2</entry><entry align="center" valign="middle">IPI00009771 (+1)</entry></row><row><entry align="center" valign="middle">LOC100130561;HMG1L10 High mobility group protein 1-like 10</entry><entry align="center" valign="middle">IPI00018755 (+3)</entry></row><row><entry align="center" valign="middle">M6PRBP1 Isoform A of Mannose-6-phosphate receptor-binding protein 1</entry><entry align="center" valign="middle">IPI00106668 (+1)</entry></row><row><entry align="center" valign="middle">MAP1B Microtubule-associated protein 1B</entry><entry align="center" valign="middle">IPI00008868</entry></row><row><entry align="center" valign="middle">MAPRE1 Microtubule-associated protein RP/EB family member 1</entry><entry align="center" valign="middle">IPI00017596</entry></row><row><entry align="center" valign="middle">MCM3 DNA replication licensing factor MCM3</entry><entry align="center" valign="middle">IPI00013214</entry></row><row><entry align="center" valign="middle">MDH1 Malate dehydrogenase, cytoplasmic</entry><entry align="center" valign="middle">IPI00291005</entry></row><row><entry align="center" valign="middle">MDH2 Malate dehydrogenase, mitochondrial precursor</entry><entry align="center" valign="middle">IPI00291006</entry></row><row><entry align="center" valign="middle">MMP14 Matrix metalloproteinase-14 precursor</entry><entry align="center" valign="middle">IPI00218398 (+1)</entry></row><row><entry align="center" valign="middle">NENF Neudesin precursor</entry><entry align="center" valign="middle">IPI00002525</entry></row><row><entry align="center" valign="middle">NIPSNAP3A Protein NipSnap homolog 3A</entry><entry align="center" valign="middle">IPI00004845 (+1)</entry></row><row><entry align="center" valign="middle">NME2 Nucleoside diphosphate kinase</entry><entry align="center" valign="middle">IPI00604590 (+1)</entry></row><row><entry align="center" valign="middle">NPC2 Epididymal secretory protein E1 precursor</entry><entry align="center" valign="middle">IPI00301579</entry></row><row><entry align="center" valign="middle">NPM1 Isoform 2 of Nucleophosmin</entry><entry align="center" valign="middle">IPI00220740 (+2)</entry></row><row><entry align="center" valign="middle">NQO2 Ribosyldihydronicotinamide dehydrogenase</entry><entry align="center" valign="middle">IPI00219129 (+3)</entry></row><row><entry align="center" valign="middle">NUDT1 Isoform p26 of 7,8-dihydro-8-oxoguanine triphosphatase</entry><entry align="center" valign="middle">IPI00004392 (+4)</entry></row><row><entry align="center" valign="middle">PARK7 Protein DJ-1</entry><entry align="center" valign="middle">IPI00298547</entry></row><row><entry align="center" valign="middle">PDAP128 kDa heat- and acid-stable phosphoprotein</entry><entry align="center" valign="middle">IPI00013297</entry></row><row><entry align="center" valign="middle">PDIA6 Isoform 2 of Protein disulfide-isomerase A6 precursor</entry><entry align="center" valign="middle">IPI00299571 (+1)</entry></row><row><entry align="center" valign="middle">PEBP1 Phosphatidylethanolamine-binding protein 1</entry><entry align="center" valign="middle">IPI00219446</entry></row><row><entry align="center" valign="middle">PGLS 6-phosphogluconolactonase</entry><entry align="center" valign="middle">IPI00029997</entry></row><row><entry align="center" valign="middle">PIR Pirin</entry><entry align="center" valign="middle">IPI00012575</entry></row><row><entry align="center" valign="middle">PNPO Pyridoxine-5'-phosphate oxidase</entry><entry align="center" valign="middle">IPI00018272 (+1)</entry></row><row><entry align="center" valign="middle">POLDIP2 Polymerase delta-interacting protein 2</entry><entry align="center" valign="middle">IPI00165506</entry></row><row><entry align="center" valign="middle">POLR2H DNA-directed RNA polymerases I, II, and III subunit RPABC3</entry><entry align="center" valign="middle">IPI00003309</entry></row><row><entry align="center" valign="middle">PPIA Peptidyl-prolyl cis-trans isomerase A</entry><entry align="center" valign="middle">IPI00419585 (+4)</entry></row><row><entry align="center" valign="middle">PPIB peptidylprolyl isomerase B precursor</entry><entry align="center" valign="middle">IPI00646304</entry></row><row><entry align="center" valign="middle">PPIF Peptidyl-prolyl cis-trans isomerase, mitochondrial precursor</entry><entry align="center" valign="middle">IPI00026519</entry></row><row><entry align="center" valign="middle">PPP1R14C Protein phosphatase 1 regulatory subunit 14C</entry><entry align="center" valign="middle">IPI00290397</entry></row><row><entry align="center" valign="middle">PRDX1 Peroxiredoxin-1</entry><entry align="center" valign="middle">IPI00000874 (+1)</entry></row><!-- EPO <DP n="50"> --><row><entry align="center" valign="middle">PRDX2 Peroxiredoxin-2</entry><entry align="center" valign="middle">IPI00027350</entry></row><row><entry align="center" valign="middle">PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial precursor</entry><entry align="center" valign="middle">IPI00024919 (+1)</entry></row><row><entry align="center" valign="middle">PRDX6 Peroxiredoxin-6</entry><entry align="center" valign="middle">IPI00220301</entry></row><row><entry align="center" valign="middle">PROCR Endothelial protein C receptor precursor</entry><entry align="center" valign="middle">IPI00009276</entry></row><row><entry align="center" valign="middle">PSPH Phosphoserine phosphatase</entry><entry align="center" valign="middle">IPI00019178</entry></row><row><entry align="center" valign="middle">PTGDS Prostaglandin-H2 D-isomerase precursor</entry><entry align="center" valign="middle">IPI00013179 (+2)</entry></row><row><entry align="center" valign="middle">PTGR1 NADP-dependent leukotriene B4 12-hydroxydehydrogenase</entry><entry align="center" valign="middle">IPI00292657</entry></row><row><entry align="center" valign="middle">PTMS Parathymosin</entry><entry align="center" valign="middle">IPI00550020</entry></row><row><entry align="center" valign="middle">QDPR Dihydropteridine reductase</entry><entry align="center" valign="middle">IPI00014439</entry></row><row><entry align="center" valign="middle">RAB11B Ras-related protein Rab-11B</entry><entry align="center" valign="middle">IPI00020436 (+2)</entry></row><row><entry align="center" valign="middle">RAB1A Isoform 1 of Ras-related protein Rab-1A</entry><entry align="center" valign="middle">IPI00005719 (+6)</entry></row><row><entry align="center" valign="middle">RAB5C Ras-related protein Rab-5C</entry><entry align="center" valign="middle">IPI00016339</entry></row><row><entry align="center" valign="middle">RAD23A UV excision repair protein RAD23 homolog A</entry><entry align="center" valign="middle">IPI00008219</entry></row><row><entry align="center" valign="middle">RALA Ras-related protein Ral-A precursor</entry><entry align="center" valign="middle">IPI00217519 (+1)</entry></row><row><entry align="center" valign="middle">RBM8A Isoform 1 of RNA-binding protein 8A</entry><entry align="center" valign="middle">IPI00001757 (+1)</entry></row><row><entry align="center" valign="middle">REXO2 Isoform 1 of Oligoribonuclease, mitochondrial precursor (Fragment)</entry><entry align="center" valign="middle">IPI00032830 (+1)</entry></row><row><entry align="center" valign="middle">RNASET2 Isoform 1 of Ribonuclease T2 precursor</entry><entry align="center" valign="middle">IPI00414896 (+1)</entry></row><row><entry align="center" valign="middle">RPE Isoform 1 of Ribulose-phosphate 3-epimerase</entry><entry align="center" valign="middle">IPI00335280 (+1)</entry></row><row><entry align="center" valign="middle">RPIA Ribose-5-phosphate isomerase</entry><entry align="center" valign="middle">IPI00026513 (+1)</entry></row><row><entry align="center" valign="middle">SAMD9 Isoform 1 of Sterile alpha motif domain-containing protein 9</entry><entry align="center" valign="middle">IPI00217018</entry></row><row><entry align="center" valign="middle">S100A11 Protein S100-A11</entry><entry align="center" valign="middle">IPI00013895</entry></row><row><entry align="center" valign="middle">S100A6 Protein S100-A6</entry><entry align="center" valign="middle">IPI00027463</entry></row><row><entry align="center" valign="middle">SCYE1 Multisynthetase complex auxiliary component p43</entry><entry align="center" valign="middle">IPI00006252 (+1)</entry></row><row><entry align="center" valign="middle">SERPINB6 Putative uncharacterized protein DKFZp686I04222</entry><entry align="center" valign="middle">IPI00413451 (+1)</entry></row><row><entry align="center" valign="middle">SMAP1 Isoform 1 of Stromal membrane-associated protein 1</entry><entry align="center" valign="middle">IPI00102096 (+2)</entry></row><row><entry align="center" valign="middle">SNX12 Isoform 1 of Sorting nexin-12</entry><entry align="center" valign="middle">IPI00438170 (+2)</entry></row><row><entry align="center" valign="middle">SOD1 Superoxide dismutase</entry><entry align="center" valign="middle">IPI00218733 (+1)</entry></row><row><entry align="center" valign="middle">SOD2 Superoxide dismutase [Mn], mitochondrial precursor</entry><entry align="center" valign="middle">IPI00022314 (+2)</entry></row><row><entry align="center" valign="middle">sp_TRYP_PIG</entry><entry align="center" valign="middle">IPIsp_TRYP_PIG</entry></row><row><entry align="center" valign="middle">SPINT2 Kunitz-type protease inhibitor 2 precursor</entry><entry align="center" valign="middle">IPI00011662</entry></row><row><entry align="center" valign="middle">STX7 Isoform 1 of Syntaxin-7</entry><entry align="center" valign="middle">IPI00289876 (+1)</entry></row><row><entry align="center" valign="middle">SUB1 Activated RNA polymerase II transcriptional coactivator p15</entry><entry align="center" valign="middle">IPI00221222</entry></row><row><entry align="center" valign="middle">TAGLN2 Transgelin-2</entry><entry align="center" valign="middle">IPI00550363</entry></row><row><entry align="center" valign="middle">TALDO1 Transaldolase</entry><entry align="center" valign="middle">IPI00744692</entry></row><row><entry align="center" valign="middle">THOC4 THO complex subunit 4</entry><entry align="center" valign="middle">IPI00328840</entry></row><row><entry align="center" valign="middle">TP5313 Isoform 1 of Putative quinone oxidoreductase</entry><entry align="center" valign="middle">IPI00384643</entry></row><row><entry align="center" valign="middle">TPI1 Isoform 1 of Triosephosphate isomerase</entry><entry align="center" valign="middle">IPI00465028</entry></row><!-- EPO <DP n="51"> --><row><entry align="center" valign="middle">TPK1 Thiamin pyrophosphokinase 1</entry><entry align="center" valign="middle">IPI00072523 (+1)</entry></row><row><entry align="center" valign="middle">TPT1 Translationally controlled tumor protein</entry><entry align="center" valign="middle">IPI00550900</entry></row><row><entry align="center" valign="middle">TRIOBP TRIO and F-actin binding protein isoform 1</entry><entry align="center" valign="middle">IPI00148768 (+8)</entry></row><row><entry align="center" valign="middle">TWF1 Isoform 3 of Twinfilin-1</entry><entry align="center" valign="middle">IPI00815767</entry></row><row><entry align="center" valign="middle">TXNDC12 Thioredoxin domain-containing protein 12 precursor</entry><entry align="center" valign="middle">IPI00026328</entry></row><row><entry align="center" valign="middle">TXNL1 Thioredoxin-like protein 1</entry><entry align="center" valign="middle">IPI00305692 (+1)</entry></row><row><entry align="center" valign="middle">UBE2I SUMO-conjugating enzyme UBC9</entry><entry align="center" valign="middle">IPI00032957 (+2)</entry></row><row><entry align="center" valign="middle">UBE2L3 Ubiquitin-conjugating enzyme E2 L3</entry><entry align="center" valign="middle">IPI00021347</entry></row><row><entry align="center" valign="middle">UBE2N Ubiquitin-conjugating enzyme E2 N</entry><entry align="center" valign="middle">IPI00003949 (+1)</entry></row><row><entry align="center" valign="middle">UCHL1 Ubiquitin carboxyl-terminal hydrolase isozyme L1</entry><entry align="center" valign="middle">IPI00018352</entry></row><row><entry align="center" valign="middle">UCHL3 Ubiquitin carboxyl-terminal hydrolase isozyme L3</entry><entry align="center" valign="middle">IPI00011250 (+1)</entry></row><row><entry align="center" valign="middle">Uncharacterized protein ENSP00000348237</entry><entry align="center" valign="middle">IPI00453476 (+1)</entry></row><row><entry align="center" valign="middle">VAPA Vesicle-associated membrane protein-associated protein A</entry><entry align="center" valign="middle">IPI00170692 (+1)</entry></row><row><entry align="center" valign="middle">VEGFA vascular endothelial growth factor A isoform a precursor</entry><entry align="center" valign="middle">IPI00012567 (+5)</entry></row><row><entry align="center" valign="middle">VPS26A Vacuolar protein sorting-associated protein 26A</entry><entry align="center" valign="middle">IPI00411426</entry></row><row><entry align="center" valign="middle">YWHAB Isoform Short of 14-3-3 protein beta/alpha</entry><entry align="center" valign="middle">IPI00759832</entry></row><row><entry align="center" valign="middle">YWHAE 14-3-3 protein epsilon</entry><entry align="center" valign="middle">IPI00000816</entry></row><row><entry align="center" valign="middle">YWHAG 14-3-3 protein gamma</entry><entry align="center" valign="middle">IPI00220642</entry></row><row><entry align="center" valign="middle">YWHAQ 14-3-3 protein theta</entry><entry align="center" valign="middle">IPI00018146</entry></row><row><entry align="center" valign="middle">YWHAZ 14-3-3 protein zeta/delta</entry><entry align="center" valign="middle">IPI00021263</entry></row><row><entry align="center" valign="middle">KRT1 Keratin, type II cytoskeletal 1</entry><entry align="center" valign="middle">IPI00220327 (+1)</entry></row><row><entry align="center" valign="middle">KRT10 Keratin, type I cytoskeletal 10</entry><entry align="center" valign="middle">IPI00009865 (+1)</entry></row><row><entry align="center" valign="middle">KRT14 Keratin, type I cytoskeletal 14</entry><entry align="center" valign="middle">IPI00384444</entry></row><row><entry align="center" valign="middle">KRT16 Keratin, type I cytoskeletal 16</entry><entry align="center" valign="middle">IPI00217963</entry></row><row><entry align="center" valign="middle">KRT17 Keratin, type I cytoskeletal 17</entry><entry align="center" valign="middle">IPI00450768</entry></row><row><entry align="center" valign="middle">KRT2 Keratin, type II cytoskeletal 2 epidermal</entry><entry align="center" valign="middle">IPI00021304 (+1)</entry></row><row><entry align="center" valign="middle">KRT27 Keratin, type I cytoskeletal 27</entry><entry align="center" valign="middle">IPI00328103</entry></row><row><entry align="center" valign="middle">KRT5 Keratin, type II cytoskeletal 5</entry><entry align="center" valign="middle">IPI00009867</entry></row><row><entry align="center" valign="middle">KRT6A Keratin, type II cytoskeletal 6A</entry><entry align="center" valign="middle">IPI00300725</entry></row><row><entry align="center" valign="middle">KRT73 Isoform 1 of Keratin, type II cytoskeletal 73</entry><entry align="center" valign="middle">IPI00174775 (+2)</entry></row><row><entry align="center" valign="middle">KRT9 Keratin, type I cytoskeletal 9</entry><entry align="center" valign="middle">IPI00019359 (+1)</entry></row><row><entry align="center" valign="middle">sp_ALBU_BOVIN</entry><entry align="center" valign="middle">IPIsp_ALBU_BOVIN</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0004" num="0004"><table frame="all"><title>Table 3: Proteins identified by MS in glioma cell line SF-539</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="100mm"/><colspec colnum="2" colname="col2" colwidth="39mm"/><thead><row><entry align="center" valign="middle"><b>Protein:</b></entry><entry align="center" valign="middle"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center" valign="middle">ACTA2 Actin, aortic smooth muscle</entry><entry align="center" valign="middle">IPI00008603 (+16)</entry></row><row><entry align="center" valign="middle">ACYP1 Acylphosphatase-1</entry><entry align="center" valign="middle">IPI00221117 (+1)</entry></row><row><entry align="center" valign="middle">ACYP2 Acylphosphatase-2</entry><entry align="center" valign="middle">IPI00216461 (+1)</entry></row><!-- EPO <DP n="52"> --><row><entry align="center" valign="middle">C19orf10 UPF0556 protein C19orf10 precursor</entry><entry align="center" valign="middle">IPI00056357</entry></row><row><entry align="center" valign="middle">COTL1 Coactosin-like protein</entry><entry align="center" valign="middle">IPI00017704</entry></row><row><entry align="center" valign="middle">CSTB Cystatin-B</entry><entry align="center" valign="middle">IPI00021828</entry></row><row><entry align="center" valign="middle">CYCS Cytochrome c</entry><entry align="center" valign="middle">IPI00465315 (+1)</entry></row><row><entry align="center" valign="middle">DBI Isoform a 1 of Acyl-CoA-binding protein</entry><entry align="center" valign="middle">IPI00010182 (+2)</entry></row><row><entry align="center" valign="middle">FKBP1A FK506-binding protein 1A</entry><entry align="center" valign="middle">IPI00873810</entry></row><row><entry align="center" valign="middle">FLG2 Filaggrin-2</entry><entry align="center" valign="middle">IPI00397801</entry></row><row><entry align="center" valign="middle">FN1 Isoform 1 of Fibronectin precursor</entry><entry align="center" valign="middle">IPI00022418 (+15)</entry></row><row><entry align="center" valign="middle">HNRNPH3 Isoform 1 of Heterogeneous nuclear ribonucleoprotein H3</entry><entry align="center" valign="middle">IPI00013877 (+3)</entry></row><row><entry align="center" valign="middle">ISG15 Interferon-induced 17 kDa protein precursor</entry><entry align="center" valign="middle">IPI00375631</entry></row><row><entry align="center" valign="middle">LGALS3 Galectin-3</entry><entry align="center" valign="middle">IPI00465431</entry></row><row><entry align="center" valign="middle">LYZ Lysozyme C precursor</entry><entry align="center" valign="middle">IPI00019038 (+1)</entry></row><row><entry align="center" valign="middle">MIF Macrophage migration inhibitory factor</entry><entry align="center" valign="middle">IPI00293276</entry></row><row><entry align="center" valign="middle">MT2A Metallothionein-2</entry><entry align="center" valign="middle">IPI00022498</entry></row><row><entry align="center" valign="middle">NEDD8 NEDD8 precursor</entry><entry align="center" valign="middle">IPI00020008 (+2)</entry></row><row><entry align="center" valign="middle">PDIA3 Protein disulfide-isomerase A3 precursor</entry><entry align="center" valign="middle">IPI00025252</entry></row><row><entry align="center" valign="middle">PFN1 Profilin-1</entry><entry align="center" valign="middle">IPI00216691</entry></row><row><entry align="center" valign="middle">RBMX Heterogeneous nuclear ribonucleoprotein G</entry><entry align="center" valign="middle">IPI00304692 (+1)</entry></row><row><entry align="center" valign="middle">RPS27A;UBC;UBB ubiquitin and ribosomal protein S27a precursor</entry><entry align="center" valign="middle">IPI00179330 (+21)</entry></row><row><entry align="center" valign="middle">S100A6 Protein S100-A6</entry><entry align="center" valign="middle">IPI00027463</entry></row><row><entry align="center" valign="middle">S100A7 Protein S100-A7</entry><entry align="center" valign="middle">IPI00219806</entry></row><row><entry align="center" valign="middle">S100A8 Protein S100-A8</entry><entry align="center" valign="middle">IPI00007047</entry></row><row><entry align="center" valign="middle">SH3BGRL SH3 domain-binding glutamic acidrich-like protein</entry><entry align="center" valign="middle">IPI00025318</entry></row><row><entry align="center" valign="middle">SH3BGRL3 Putative uncharacterized protein</entry><entry align="center" valign="middle">IPI00010402 (+2)</entry></row><row><entry align="center" valign="middle">sp_B2MG_HUMAN</entry><entry align="center" valign="middle">IPIsp_B2MG_HUMAN</entry></row><row><entry align="center" valign="middle">TMSB10 Thymosin beta-10</entry><entry align="center" valign="middle">IPI00220827</entry></row><row><entry align="center" valign="middle">TXN Thioredoxin</entry><entry align="center" valign="middle">IPI00216298 (+1)</entry></row><row><entry align="center" valign="middle">TXNDC17 Thioredoxin domain-containing protein 17</entry><entry align="center" valign="middle">IPI00646689</entry></row><row><entry align="center" valign="middle">UFM1 Ubiquitin-fold modifier 1 precursor</entry><entry align="center" valign="middle">IPI00010207 (+1)</entry></row><row><entry align="center" valign="middle">KPRP Keratinocyte proline-rich protein</entry><entry align="center" valign="middle">IPI00514908</entry></row><row><entry align="center" valign="middle">KRT1 Keratin, type II cytoskeletal 1</entry><entry align="center" valign="middle">IPI00220327 (+1)</entry></row><row><entry align="center" valign="middle">KRT10 Keratin, type I cytoskeletal 10</entry><entry align="center" valign="middle">IPI00009865</entry></row><row><entry align="center" valign="middle">KRT14 Keratin, type I cytoskeletal 14</entry><entry align="center" valign="middle">IPI00384444</entry></row><row><entry align="center" valign="middle">KRT2 Keratin, type II cytoskeletal 2 epidermal</entry><entry align="center" valign="middle">IPI00021304 (+1)</entry></row><row><entry align="center" valign="middle">KRT5 Keratin, type II cytoskeletal 5</entry><entry align="center" valign="middle">IPI00009867</entry></row><row><entry align="center" valign="middle">KRT77 Keratin 77</entry><entry align="center" valign="middle">IPI00376379</entry></row><row><entry align="center" valign="middle">KRT9 Keratin, type I cytoskeletal 9</entry><entry align="center" valign="middle">IPI00019359 (+1)</entry></row><row><entry align="center" valign="middle">sp_TRYP_PIG</entry><entry align="center" valign="middle">IPIsp_TRYP_PIG</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="53"> -->
<tables id="tabl0005" num="0005"><table frame="all"><title>Table 4: Proteins identified by MS from Glioma cell line U251 supernatants:</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="117mm"/><colspec colnum="2" colname="col2" colwidth="49mm"/><thead><row><entry align="center" valign="middle"><b>Protein:</b></entry><entry align="center" valign="middle"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center" valign="middle">A1BG Alpha-1B-glycoprotein precursor</entry><entry align="center" valign="middle">IPI00022895</entry></row><row><entry align="center" valign="middle">A2M Alpha-2-macroglobulin precursor</entry><entry align="center" valign="middle">IPI00478003</entry></row><row><entry align="center" valign="middle">C3 Complement C3 precursor (Fragment)</entry><entry align="center" valign="middle">IPI00783987</entry></row><row><entry align="center" valign="middle">FGG Isoform Gamma-B of Fibrinogen gamma chain precursor</entry><entry align="center" valign="middle">IPI00021891 (+3)</entry></row><row><entry align="center" valign="middle">GLUD1 Glutamate dehydrogenase 1, mitochondnal precursor</entry><entry align="center" valign="middle">IPI00016801 (+1)</entry></row><row><entry align="center" valign="middle">HBA2;HBA1 Hemoglobin subunit alpha</entry><entry align="center" valign="middle">IPI00410714 (+1)</entry></row><row><entry align="center" valign="middle">HBB Hemoglobin subunit beta</entry><entry align="center" valign="middle">IPI00654755 (+1)</entry></row><row><entry align="center" valign="middle">HPX Hemopexin precursor</entry><entry align="center" valign="middle">IPI00022488</entry></row><row><entry align="center" valign="middle">IGHG1 IGHG1 protein</entry><entry align="center" valign="middle">IPI00448925</entry></row><row><entry align="center" valign="middle">IGHM IGHM protein</entry><entry align="center" valign="middle">IPI00477090</entry></row><row><entry align="center" valign="middle">IGHV3OR16-13;IGHA1 IGHA1 protein</entry><entry align="center" valign="middle">IPI00166866 (+1)</entry></row><row><entry align="center" valign="middle">LDHB L-lactate dehydrogenase B chain</entry><entry align="center" valign="middle">IPI00219217</entry></row><row><entry align="center" valign="middle">LOC100133739 Putative uncharacterized protein DKFZp686C15213</entry><entry align="center" valign="middle">IPI00426051</entry></row><row><entry align="center" valign="middle">LTF Growth-inhibiting protein 12</entry><entry align="center" valign="middle">IPI00298860 (+3)</entry></row><row><entry align="center" valign="middle">MAGI1 Isoform 4 of Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1</entry><entry align="center" valign="middle">IPI00382692</entry></row><row><entry align="center" valign="middle">MPO Isoform H17 of Myeloperoxidase precursor</entry><entry align="center" valign="middle">IPI00007244 (+2)</entry></row><row><entry align="center" valign="middle">SERPINA1 Isoform 1 of Alpha-1-antitrypsin precursor</entry><entry align="center" valign="middle">IPI00553177 (+1)</entry></row><row><entry align="center" valign="middle">SERPINA3 Alpha-1-antichymotrypsin precursor</entry><entry align="center" valign="middle">IPI00550991 (+1)</entry></row><row><entry align="center" valign="middle">TF Serotransferrin precursor</entry><entry align="center" valign="middle">IPI00022463 (+2)</entry></row><row><entry align="center" valign="middle">ALB Isoform 1 of Serum albumin precursor</entry><entry align="center" valign="middle">IPI00745872 (+1)</entry></row><row><entry align="center" valign="middle">KRT1 Keratin, type II cytoskeletal 1</entry><entry align="center" valign="middle">IPI00220327 (+1)</entry></row><row><entry align="center" valign="middle">KRT10 Keratin, type I cytoskeletal 10</entry><entry align="center" valign="middle">IPI00009865 (+1)</entry></row><row><entry align="center" valign="middle">KRT14 Keratin, type I cytoskeletal 14</entry><entry align="center" valign="middle">IPI00384444</entry></row><row><entry align="center" valign="middle">KRT2 Keratin, type II cytoskeletal 2 epidermal</entry><entry align="center" valign="middle">IPI00021304 (+1)</entry></row><row><entry align="center" valign="middle">KRT5 Keratin, type II cytoskeletal 5</entry><entry align="center" valign="middle">IPI00009867</entry></row><row><entry align="center" valign="middle">KRT6C Keratin, type II cytoskeletal 6C</entry><entry align="center" valign="middle">IPI00299145</entry></row><row><entry align="center" valign="middle">KRT9 Keratin, type I cytoskeletal 9</entry><entry align="center" valign="middle">IPI00019359 (+1)</entry></row><row><entry align="center" valign="middle">sp_ALBU_BOVIN</entry><entry align="center" valign="middle">IPIsp_ALBU_BOVIN</entry></row><row><entry align="center" valign="middle">sp_TRYP_PIG</entry><entry align="center" valign="middle">IPIsp_TRYP_PIG</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0006" num="0006"><table frame="all"><title>Table 5: Proteins identified by MS of supernatants from colon cell line HCC-2998:</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="97mm"/><colspec colnum="2" colname="col2" colwidth="58mm"/><thead><row><entry align="center" valign="middle"><b>Protein:</b></entry><entry align="center" valign="middle"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center" valign="middle">RPS27A;UBC;UBB ubiquitin and ribosomal protein S27a precursor</entry><entry align="center" valign="middle">IPI00179330</entry></row><row><entry align="center" valign="middle">S100A6 Protein S100-A6</entry><entry align="center" valign="middle">IPI00027463</entry></row><row><entry align="center" valign="middle">S100A7 Protein S100-A7</entry><entry align="center" valign="middle">IPI00219806</entry></row><row><entry align="center" valign="middle">S100A8 Protein S100-A8</entry><entry align="center" valign="middle">IPI00007047</entry></row><row><entry align="center" valign="middle">S100A9 Protein S100-A9</entry><entry align="center" valign="middle">IPI00027462</entry></row><row><entry align="center" valign="middle">SERPINB3 Isoform 1 of Serpin B3</entry><entry align="center" valign="middle">IPI00022204</entry></row><row><entry align="center" valign="middle">KRT1 Keratin, type II cytoskeletal 1</entry><entry align="center" valign="middle">IPI00220327</entry></row><!-- EPO <DP n="54"> --><row><entry align="center" valign="middle">KRT10 Keratin, type I cytoskeletal 10</entry><entry align="center" valign="middle">IPI00009865</entry></row><row><entry align="center" valign="middle">KRT2 Keratin, type II cytoskeletal 2 epidermal</entry><entry align="center" valign="middle">IPI00021304</entry></row><row><entry align="center" valign="middle">KRT9 Keratin, type I cytoskeletal 9</entry><entry align="center" valign="middle">IPI00019359</entry></row><row><entry align="center" valign="middle">sp_TRYP_PIG IPIsp_TRYP_PIG 24 kDa 14</entry><entry align="center" valign="middle"/></row></tbody></tgroup></table></tables>
<tables id="tabl0007" num="0007"><table frame="all"><title>Table 6: Proteins identified by MS of supernatants from hepatic cell line HepG2:</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="99mm"/><colspec colnum="2" colname="col2" colwidth="54mm"/><thead><row><entry align="center" valign="middle"><b>Protein:</b></entry><entry align="center" valign="middle"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center" valign="middle">B2M Beta-2-microglobulin precursor</entry><entry align="center" valign="middle">IPI00004656</entry></row><row><entry align="center" valign="middle">C19orf10 Uncharacterized protein C19orf10 precursor</entry><entry align="center" valign="middle">IPI00056357</entry></row><row><entry align="center" valign="middle">CSTB Cystatm-B</entry><entry align="center" valign="middle">IPI00021828</entry></row><row><entry align="center" valign="middle">CYCS Cytochrome c</entry><entry align="center" valign="middle">IPI00465315</entry></row><row><entry align="center" valign="middle">HMGA1 Isoform HMG-I of High mobility group protein HMGI/HMG-Y</entry><entry align="center" valign="middle">IPI00179700</entry></row><row><entry align="center" valign="middle">LGALS3 Galectin-3</entry><entry align="center" valign="middle">IPI00465431</entry></row><row><entry align="center" valign="middle">MIF Macrophage migration inhibitory factor</entry><entry align="center" valign="middle">IPI00293276</entry></row><row><entry align="center" valign="middle">PFN1 Profilin-1</entry><entry align="center" valign="middle">IPI00216691</entry></row><row><entry align="center" valign="middle">PPIA;LOC654188;LOC653214 Peptidyl-prolyl cis-trans isomerase A</entry><entry align="center" valign="middle">IPI00419585</entry></row><row><entry align="center" valign="middle">RNASE4 Ribonuclease 4 precursor</entry><entry align="center" valign="middle">IPI00029699</entry></row><row><entry align="center" valign="middle">S100A6 Protein S100-A6</entry><entry align="center" valign="middle">IPI00027463</entry></row><row><entry align="center" valign="middle">UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor</entry><entry align="center" valign="middle">IPI00179330</entry></row><row><entry align="center" valign="middle">KRT1 Keratin, type II cytoskeletal 1</entry><entry align="center" valign="middle">IPI00220327</entry></row><row><entry align="center" valign="middle">KRT10 Keratin, type I cytoskeletal 10</entry><entry align="center" valign="middle">IPI00009865</entry></row><row><entry align="center" valign="middle">KRT16 Keratin, type I cytoskeletal 16</entry><entry align="center" valign="middle">IPI00217963</entry></row><row><entry align="center" valign="middle">KRT2 Keratin, type II cytoskeletal 2 epidermal</entry><entry align="center" valign="middle">IPI00021304</entry></row><row><entry align="center" valign="middle">KRT9 Keratin, type I cytoskeletal 9</entry><entry align="center" valign="middle">IPI00019359</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0008" num="0008"><table frame="all"><title>Table 7: Proteins identified by MS of supernatants from ovarian cell line CRL-1978:</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="98mm"/><colspec colnum="2" colname="col2" colwidth="58mm"/><thead><row><entry namest="col1" nameend="col2" align="center" valign="middle">Proteins Identified by MS analysis of Chemorepellant Fractions of Cell Line CRL-1978</entry></row><row><entry align="center" valign="middle"><b>Identified Proteins:</b></entry><entry align="center" valign="middle"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center" valign="middle">ALB Serum albumin</entry><entry align="center" valign="middle">IPI00022434</entry></row><row><entry align="center" valign="middle">B2M Beta-2-microglobulin precursor</entry><entry align="center" valign="middle">IPI00004656</entry></row><row><entry align="center" valign="middle">C19orf10 Uncharacterized protein C19orf10 precursor</entry><entry align="center" valign="middle">IPI00056357</entry></row><row><entry align="center" valign="middle">CST1 Cystatin-SN precursor</entry><entry align="center" valign="middle">IPI00305477</entry></row><row><entry align="center" valign="middle">CST3 Cystatin-C precursor</entry><entry align="center" valign="middle">IPI00032293</entry></row><row><entry align="center" valign="middle">CST4 Cystatin-S precursor</entry><entry align="center" valign="middle">IPI00032294</entry></row><row><entry align="center" valign="middle">CYCS Cytochrome c</entry><entry align="center" valign="middle">IPI00465315</entry></row><row><entry align="center" valign="middle">FAM3C Protein FAM3C precursor</entry><entry align="center" valign="middle">IPI00021923</entry></row><row><entry align="center" valign="middle">ISG15 Interferon-induced 17 kDa protein precursor</entry><entry align="center" valign="middle">IPI00375631</entry></row><row><entry align="center" valign="middle">KRT1 Keratin, type II cytoskeletal 1</entry><entry align="center" valign="middle">IPI00220327</entry></row><row><entry align="center" valign="middle">KRT10 Keratin, type I cytoskeletal 10</entry><entry align="center" valign="middle">IPI00009865</entry></row><!-- EPO <DP n="55"> --><row><entry align="center" valign="middle">KRT14 Keratin, type I cytoskeletal 14</entry><entry align="center" valign="middle">IPI00384444</entry></row><row><entry align="center" valign="middle">KRT2 Keratin, type II cytoskeletal 2 epidermal</entry><entry align="center" valign="middle">IPI00021304</entry></row><row><entry align="center" valign="middle">KRT9 Keratin, type I cytoskeletal 9</entry><entry align="center" valign="middle">IPI00019359</entry></row><row><entry align="center" valign="middle">PFN1 Profilin-1</entry><entry align="center" valign="middle">IPI00216691</entry></row><row><entry align="center" valign="middle">PPIA;LOC654188;LOC653214 Peptidyl-prolyl cis-trans isomerase A</entry><entry align="center" valign="middle">IPI00419585</entry></row><row><entry align="center" valign="middle">PPIB peptidylprolyl isomerase B precursor</entry><entry align="center" valign="middle">IPI00646304</entry></row><row><entry align="center" valign="middle">S100A6 Protein S100-A6</entry><entry align="center" valign="middle">IPI00027463</entry></row><row><entry align="center" valign="middle">TXN Thioredoxin</entry><entry align="center" valign="middle">IPI00216298</entry></row><row><entry align="center" valign="middle">UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor</entry><entry align="center" valign="middle">IPI00179330</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0009" num="0009"><table frame="all"><title>Table 8: Proteins identified by MS of supernatants from prostate cell line PC3 and ovarian cell line CRL-1978:</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="100mm"/><colspec colnum="2" colname="col2" colwidth="66mm"/><thead><row><entry namest="col1" nameend="col2" align="center">Proteins Identified by MS analysis of Chemorepellant Fractions of Cell Line PC3</entry></row><row><entry align="center"><b>Identified Proteins:</b></entry><entry align="center"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center" valign="bottom">AGR2 AGR2</entry><entry align="center" valign="bottom">IPI00007427</entry></row><row><entry align="center" valign="bottom">ALB Serum albumin</entry><entry align="center" valign="bottom">IPI00022434</entry></row><row><entry align="center" valign="bottom">ARMET ARMET protein precursor</entry><entry align="center" valign="bottom">IPI00328748</entry></row><row><entry align="center" valign="bottom">C7orf24 Uncharacterized protein C7orf24</entry><entry align="center" valign="bottom">IPI00031564</entry></row><row><entry align="center" valign="bottom">COTL1 Coactosin-like protein</entry><entry align="center" valign="bottom">IPI00017704</entry></row><row><entry align="center" valign="bottom">FAM3C Protein FAM3C precursor</entry><entry align="center" valign="bottom">IPI00021923</entry></row><row><entry align="center" valign="bottom">HNRPA2B1 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1</entry><entry align="center" valign="bottom">IPI00396378</entry></row><row><entry align="center" valign="bottom">HSPG2 Basement membrane-specific heparan sulfate proteoglycan core protein precursor</entry><entry align="center" valign="bottom">IPI00024284</entry></row><row><entry align="center" valign="bottom">KRT1 Keratin, type II cytoskeletal 1</entry><entry align="center" valign="bottom">IPI00220327</entry></row><row><entry align="center" valign="bottom">KRT10 Keratin, type I cytoskeletal 10</entry><entry align="center" valign="bottom">IPI00009865</entry></row><row><entry align="center" valign="bottom">KRT14 Keratin, type I cytoskeletal 14</entry><entry align="center" valign="bottom">IPI00384444</entry></row><row><entry align="center" valign="bottom">KRT16 Keratin, type I cytoskeletal 16</entry><entry align="center" valign="bottom">IPI00217963</entry></row><row><entry align="center" valign="bottom">KRT2 Keratin, type II cytoskeletal 2 epidermal</entry><entry align="center" valign="bottom">IPI00021304</entry></row><row><entry align="center" valign="bottom">KRT5 Keratin, type II cytoskeletal 5</entry><entry align="center" valign="bottom">IPI00009867</entry></row><row><entry align="center" valign="bottom">KRT6A Keratin, type II cytoskeletal 6A</entry><entry align="center" valign="bottom">IPI00300725</entry></row><row><entry align="center" valign="bottom">KRT9 Keratin, type I cytoskeletal 9</entry><entry align="center" valign="bottom">IPI00019359</entry></row><row><entry align="center" valign="bottom">LCN2 Neutrophil gelatinase-associated lipocalin precursor</entry><entry align="center" valign="bottom">IPI00299547</entry></row><row><entry align="center" valign="bottom">LMNA Isoform A of Lamin-A/C</entry><entry align="center" valign="bottom">IPI00021405</entry></row><row><entry align="center" valign="bottom">NME1;NME1-NME2;NME2 NME1-NME2 protein</entry><entry align="center" valign="bottom">IPI00795292</entry></row><row><entry align="center" valign="bottom">NPC2 Epididymal secretory protein E1 precursor</entry><entry align="center" valign="bottom">IPI00301579</entry></row><row><entry align="center" valign="bottom">PARK7 Protein DJ-1</entry><entry align="center" valign="bottom">IPI00298547</entry></row><row><entry align="center" valign="bottom">PEBP1 Phosphatidylethanolamine-binding protein 1</entry><entry align="center" valign="bottom">IPI00219446</entry></row><row><entry align="center" valign="bottom">PPIA;LOC654188;LOC653214 Peptidyl-prolyl cis-trans isomerase A</entry><entry align="center" valign="bottom">IPI00419585</entry></row><row><entry align="center" valign="bottom">PPIB peptidylprolyl isomerase B precursor</entry><entry align="center" valign="bottom">IPI00646304</entry></row><!-- EPO <DP n="56"> --><row><entry align="center" valign="bottom">PRDX1 Peroxiredoxin-1</entry><entry align="center" valign="bottom">IPI00000874</entry></row><row><entry align="center" valign="bottom">PRDX6 Peroxiredoxin-6</entry><entry align="center" valign="bottom">IPI00220301</entry></row><row><entry align="center" valign="bottom">RBP4 Plasma retinol-binding protein precursor</entry><entry align="center" valign="bottom">IPI00022420</entry></row><row><entry align="center" valign="bottom">TAGLN2 Transgelin-2</entry><entry align="center" valign="bottom">IPI00550363</entry></row><row><entry align="center" valign="bottom">TFF2 Trefoil factor 2 precursor</entry><entry align="center" valign="bottom">IPI00010675</entry></row><row><entry align="center" valign="bottom">TIMP2 Metalloproteinase inhibitor 2 precursor</entry><entry align="center" valign="bottom">IPI00027166</entry></row><row><entry align="center" valign="bottom">TPT1 Tumor protein, translationally-controlled 1</entry><entry align="center" valign="bottom">IPI00009943</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0010" num="0010"><table frame="all"><title>Table 9: Proteins identified by MS of supernatants from breast cancer cell line SK-BR-3:</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="107mm"/><colspec colnum="2" colname="col2" colwidth="59mm"/><thead><row><entry align="center" valign="middle"><b>Protein:</b></entry><entry align="center" valign="middle"><b>Accession #</b></entry></row></thead><tbody><row><entry align="center">TRFE_HU Serotransferrin precursor (Transferrin) (Siderophilin)</entry><entry align="center">P02787</entry></row><row><entry align="center">EF1G_HU Elongation factor 1-gamma (EF-1-gamma)</entry><entry align="center">P26641</entry></row><row><entry align="center">LG3BP_HU galectin 3 binding protein precursor (Lectin galactoside-binding soluble 3-binding protein)</entry><entry align="center">Q08380</entry></row></tbody></tgroup></table></tables></p><p id="p0113" num="0113">As shown in the figures, the following proteins were identified in chemorepulsive fractions of supernatants from cell lines and/or ovarian cystic fluid were shown to induce negative chemotaxis of neutrophils:
<ul><li>actin, 14-3-3 zeta/delta, apolipoprotein A1, hemopexin, PARK7, cofilin-1, 14-3-3 epsilon, 14-3-3- gamma, phosphoserine phosphatase, superoxide dismutase, profilin-1, beta-2 microglobulin, cytochrome c, cystatin B, macrophage migration inhibitory factor (MIF), FK506 binding protein, thioredoxin, galectin 3, human transferrin, human EF-1-gamma and human galectin 3 binding protein.</li></ul></p><p id="p0114" num="0114">Profilin-1 was identified in chemorepulsive supernatant fractions. As shown in the figures, profilin-2 was shown to induce negative chemotaxis.</p><heading id="h0020"><u>Example 3: Chemorepellant proteins identified in multiple chemorepellant fractions</u></heading><p id="p0115" num="0115">Table 10 shows chemorepellant proteins that were isolated from chemorepellant fractions of at least two cells or from a cell line and ovarian cystic fluid (as indicated by an "X") and were shown to induce chemorepulsion of neutrophils in their purified form (as described in Examples 1 and 2). For example, Actin was identified in the chemorepulsive fractions isolated from the supernatant of SF-539 cells and from ovarian cystic fluid sample (described in Example 1).<!-- EPO <DP n="57"> -->
<tables id="tabl0011" num="0011"><table frame="all"><title>Table 10: Proteins identified in the chemorepellant fractions of at least two cell lines</title><tgroup cols="8"><colspec colnum="1" colname="col1" colwidth="57mm"/><colspec colnum="2" colname="col2" colwidth="20mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="16mm"/><colspec colnum="5" colname="col5" colwidth="15mm"/><colspec colnum="6" colname="col6" colwidth="14mm"/><colspec colnum="7" colname="col7" colwidth="14mm"/><colspec colnum="8" colname="col8" colwidth="18mm"/><thead><row><entry valign="top"/><entry namest="col2" nameend="col8" align="center" valign="top">Cell Line/ Tumor</entry></row></thead><tbody><row><entry>Proteins isolated from supernatants</entry><entry>CRL-1978</entry><entry>PC-3</entry><entry>SF-539</entry><entry>HepG2</entry><entry>786-O</entry><entry>ACHN</entry><entry>OCI-856</entry></row><row><entry>ACTA2 (Actin, aortic smooth muscle)</entry><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center">X</entry></row><row><entry>B2M (beta-2 microglobulin precursor)</entry><entry align="center">X</entry><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/><entry align="center"/><entry align="center"/></row><row><entry>CFL1 (Cofilin-1)</entry><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/></row><row><entry>CSTB (cystatin B)</entry><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/><entry align="center"/><entry align="center"/></row><row><entry>CYCS (cytochrome C)</entry><entry align="center">X</entry><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/><entry align="center"/><entry align="center"/></row><row><entry>LGAL3 (galectin-3)</entry><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/><entry align="center"/><entry align="center"/></row><row><entry>MIF (macrophage migration inhibitory factor)</entry><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/><entry align="center"/><entry align="center"/></row><row><entry>PARK7 Protein DJ-1</entry><entry align="center"/><entry align="center">X</entry><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/></row><row><entry>PSPH (phosphoserine phosphatase)</entry><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/></row><row><entry>SOD1 (superoxide dismutase</entry><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/></row><row><entry>TXN (thioredoxin)</entry><entry align="center">X</entry><entry align="center"/><entry align="center">X</entry><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center"/></row><row><entry>YWHAE 14-3-3 epsilon</entry><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center"/></row><row><entry>YWHAZ (14-3-3 zeta/delta)</entry><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center"/><entry align="center">X</entry><entry align="center">X</entry><entry align="center">X</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0012" num="0012"><table frame="all"><title>Table 11 lists proteins identified in chemorepellant fractions of at least two cell lines or at least one cell line and ovarian cyst fluid.</title><tgroup cols="11" rowsep="0"><colspec colnum="1" colname="col1" colwidth="37mm"/><colspec colnum="2" colname="col2" colwidth="14mm"/><colspec colnum="3" colname="col3" colwidth="12mm"/><colspec colnum="4" colname="col4" colwidth="12mm"/><colspec colnum="5" colname="col5" colwidth="16mm"/><colspec colnum="6" colname="col6" colwidth="12mm"/><colspec colnum="7" colname="col7" colwidth="14mm"/><colspec colnum="8" colname="col8" colwidth="13mm"/><colspec colnum="9" colname="col9" colwidth="15mm"/><colspec colnum="10" colname="col10" colwidth="12mm"/><colspec colnum="11" colname="col11" colwidth="14mm"/><thead><row><entry valign="middle">Table 11A: Proteins identified in chemorepellant fractions of at least</entry><entry align="center" valign="middle">CRL-1978</entry><entry align="center" valign="middle">PC-3</entry><entry align="center" valign="middle">SF-539</entry><entry align="center" valign="middle">HepG2</entry><entry align="center" valign="middle">SK-BR-3</entry><entry align="center" valign="middle">HCC-2998</entry><entry align="center" valign="middle">786-O</entry><entry align="center" valign="middle">ACHN</entry><entry align="center" valign="middle">U-251</entry><entry align="center" valign="middle">OCI-856 (Cyst fluid)</entry></row></thead><tbody><row><entry valign="middle">ACBD3 Golgi resident protein GCP60</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><!-- EPO <DP n="58"> --><row><entry valign="middle">APOA1BP Isoform 1 of Apolipoprotein A-I-binding protein precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">ARHGDIA Rho GDP-dissociation inhibitor 1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">ARMET ARMET protein precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">C19orf10 Uncharacterized protein C19orf10 precursor</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">C19orf33 Isoform 1 of Immortalization up-regulated protein</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">C1orf128 Isoform 1 of UPF0424 protein C1orf128</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">C7orf24 Uncharacterized protein C7orf24</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CALD1 Isoform 4 of Caldesmon</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CALM2;CALM1;CAL M3 Calmodulin</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CFL1 Cofilin-1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CFL2 Cofilin-2</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CIAPIN1 Isoform 3 of Anamorsin</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CNPY2 Isoform 1 of Protein canopy homolog 2 precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">COTL1 Coactosin-like protein</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CRK v-crk sarcoma virus CT10 oncogene homolog isoform b</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CSTB Cystatin-B</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CYCS Cytochrome c</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">CYR61 CYR61 protein</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">DSTN Destrin</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">DTD1 D-tyrosyl-tRNA(Tyr) deacylase 1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><!-- EPO <DP n="59"> --><row><entry valign="middle">EEF1G Elongation factor 1-gamma</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">EIF4B Eukaryotic translation initiation factor 4B</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">EIF6 Eukaryotic translation initiation factor 6</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">FAHD1 Isoform 2 of Fumarylacetoacetate hydrolase domain-containing protein 1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">FAM3C Protein FAM3C precursor</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">FER1L3 Isoform 1 of Myoferlin</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">GLO1 Lactoylglutathione lyase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">GSTP1 Glutathione S-transferase P</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">HDDC2 Isoform 2 of HD domain-containing protein 2</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">HMGA1 Isoform HMG-I of High mobility group protein HMGI/HMG-Y</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">HMGN1 Non-histone chromosomal protein HMG-14</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">HN1 Isoform 1 of Hematological and neurological expressed 1 protein</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">HNRNPA2B1 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">HPRT1 Hypoxanthine-guanine phosphoribosyltransf erase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">ISG15 Interferon-induced 17 kDa protein precursor</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">KIAA0174 Isoform 1 of Uncharacterized protein KIAA0174</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">LDHB L-lactate dehydrogenase B chain</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/></row><row><entry valign="middle">LGALS3 Galectin-3</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">LMNA Isoform A of Lamin-A/C</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><!-- EPO <DP n="60"> --><row><entry valign="middle">M6PRBP1 Isoform A of Mannose-6-phosphate receptor-binding protein 1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">MAPRE1 Microtubule-associated protein RP/EB family member 1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">NME2 Nucleoside diphosphate kinase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">NPC2 Epididymal secretory protein E1 precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">NQO2 Ribosyldihydronicotin amide dehydrogenase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">NUDT1 Isoform p26 of 7,8-dihydro-8-oxoguanine triphosphatase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PDAP1 28 kDa heat-and acid-stable phosphoprotein</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PEBP1 Phosphatidylethanola mine-binding protein 1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PFN1 Profilin-1</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PPIA;LOC654188;LO C653214 Peptidyl-prolyl cis-trans isomerase A</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PPIB peptidylprolyl isomerase B precursor</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PPIF Peptidyl-prolyl cis-trans isomerase, mitochondrial precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PRDX1 Peroxiredoxin-1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">PRDX6 Peroxiredoxin-6</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">QDPR Dihydropteridine reductase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">RAB11B Ras-related protein Rab-11B</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><!-- EPO <DP n="61"> --><row><entry valign="middle">REXO2 Isoform 1 of Oligoribonuclease, mitochondrial precursor (Fragment)</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">RNASET2 Isoform 1 of Ribonuclease T2 precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">RPE Isoform 1 of Ribulose-phosphate 3-epimerase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">RPIA Ribose-5-phosphate isomerase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">RPS27A;UBC;UBB ubiquitin and ribosomal protein S27a precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">S100A11 Protein S100-A11</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">S100A6 Protein S100-A6</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">S100A7 Protein S100-A7</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">S100A8 Protein S100-A8</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">SCYE1 Multisynthetase complex auxiliary component p43</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">SNX12 Isoform 1 of Sorting nexin-12</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">STX7 Isoform 1 of Syntaxin-7</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">SUB1 Activated RNA polymerase II transcriptional coactivator p15</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">TAGLN2 Transgelin-2</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">TPI1 Isoform 1 of Triosephosphate isomerase</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">TPK1 Thiamin pyrophosphokinase 1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">TPT1 Translationally-controlled tumor protein</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">TRFE Human Serotransferrin precursor (Transferrin) (Siderophilin)</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry></row><row><entry valign="middle">TWF1 Isoform 3 of Twinfilin-1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">TXNDC12 Thioredoxin domain-containing protein 12 precursor</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><!-- EPO <DP n="62"> --><row><entry valign="middle">UBC,RPS27A,UBB ubiquitin and ribosomal protein S27a precursor</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">UBE2I SUMO-conjugating enzyme UBC9</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">UBE2L3 Ubiquitin-conjugating enzyme E2 L3</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">UCHL1 Ubiquitin carboxyl-terminal hydrolase isozyme L1</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">VAPA Vesicle-associated membrane protein-associated protein A</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">YWHAB Isoform Short of 14-3-3 protein beta/alpha</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">YWHAE 14-3-3 protein epsilon</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry valign="middle">YWHAZ 14-3-3 protein zeta/delta</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry><entry align="center" valign="middle">X</entry><entry align="center" valign="middle"/><entry align="center" valign="middle">X</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0013" num="0013"><table frame="all"><title><u>TABLE 11B: Accession numbers for proteins listed in Table 11A</u></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="36mm"/><colspec colnum="2" colname="col2" colwidth="115mm"/><thead><row><entry align="center" valign="middle"><b>Accession #</b></entry><entry valign="middle"><b>Protein Name</b></entry></row></thead><tbody><row><entry align="center" valign="middle">IPI00009315</entry><entry valign="middle">ACBD3 Golgi resident protein GCP60</entry></row><row><entry align="center" valign="middle">IPI00168479 (+1)</entry><entry valign="middle">APOA1BP Isoform 1 of Apolipoprotein A-I-binding protein precursor</entry></row><row><entry align="center" valign="middle">IPI00003815 (+1)</entry><entry valign="middle">ARHGDIA Rho GDP-dissociation inhibitor 1</entry></row><row><entry align="center" valign="middle">IPI00328748</entry><entry valign="middle">ARMET ARMET protein precursor</entry></row><row><entry align="center" valign="middle">IPI00056357</entry><entry valign="middle">C19orf10 Uncharacterized protein C19orf10 precursor</entry></row><row><entry align="center" valign="middle">IPI00030767</entry><entry valign="middle">C19orf33 Isoform 1 of Immortalization up-regulated protein</entry></row><row><entry align="center" valign="middle">IPI00015351</entry><entry valign="middle">Clorf128 Isoform 1 of UPF0424 protein C1orf128</entry></row><row><entry align="center" valign="middle">IPI00031564</entry><entry valign="middle">C7orf24 Uncharacterized protein C7orf24</entry></row><row><entry align="center" valign="middle">IPI00218696</entry><entry valign="middle">CALD1 Isoform 4 of Caldesmon</entry></row><row><entry align="center" valign="middle">IPI00075248 (+2)</entry><entry valign="middle">CALM2;CALM1;CALM3 Calmodulin</entry></row><row><entry align="center" valign="middle">IPI00012011</entry><entry valign="middle">CFL1 Cofilin-1</entry></row><row><entry align="center" valign="middle">IPI00413344</entry><entry valign="middle">CFL2 Cofilin-2</entry></row><row><entry align="center" valign="middle">IPI00025333 (+1)</entry><entry valign="middle">CIAPIN1 Isoform 3 of Anamorsin</entry></row><row><entry align="center" valign="middle">IPI00443909</entry><entry valign="middle">CNPY2 Isoform 1 of Protein canopy homolog 2 precursor</entry></row><!-- EPO <DP n="63"> --><row><entry align="center" valign="middle">IPI00017704</entry><entry valign="middle">COTL1 Coactosin-like protein</entry></row><row><entry align="center" valign="middle">IPI00305469</entry><entry valign="middle">CRK v-crk sarcoma virus CT10 oncogene homolog isoform b</entry></row><row><entry align="center" valign="middle">IPI00021828</entry><entry valign="middle">CSTB Cystatin-B</entry></row><row><entry align="center" valign="middle">IPI00465315</entry><entry valign="middle">CYCS Cytochrome c</entry></row><row><entry align="center" valign="middle">IPI00006273 (+2)</entry><entry valign="middle">CYR61 CYR61 protein</entry></row><row><entry align="center" valign="middle">IPI00473014</entry><entry valign="middle">DSTN Destrin</entry></row><row><entry align="center" valign="middle">IPI00152692</entry><entry valign="middle">DTD1 D-tyrosyl-tRNA(Tyr) deacylase 1</entry></row><row><entry align="center" valign="middle">IPI00000875 (+1)</entry><entry valign="middle">EEF1G Elongation factor 1-gamma</entry></row><row><entry align="center" valign="middle">IPI00012079 (+1)</entry><entry valign="middle">EIF4B Eukaryotic translation initiation factor 4B</entry></row><row><entry align="center" valign="middle">IPI00010105</entry><entry valign="middle">EIF6 Eukaryotic translation initiation factor 6</entry></row><row><entry align="center" valign="middle">IPI00440828 (+2)</entry><entry valign="middle">FAHD1 Isoform 2 of Fumarylacetoacetate hydrolase domain-containing protein 1</entry></row><row><entry align="center" valign="middle">IPI00021923</entry><entry valign="middle">FAM3C Protein FAM3C precursor</entry></row><row><entry align="center" valign="middle">IPI00021048 (+5)</entry><entry valign="middle">FER1L3 Isoform 1 of Myoferlin</entry></row><row><entry align="center" valign="middle">IPI00220766</entry><entry valign="middle">GLO1 Lactoylglutathione lyase</entry></row><row><entry align="center" valign="middle">IPI00219757 (+1)</entry><entry valign="middle">GSTP1 Glutathione S-transferase P</entry></row><row><entry align="center" valign="middle">IPI00386751 (+1)</entry><entry valign="middle">HDDC2 Isoform 2 of HD domain-containing protein 2</entry></row><row><entry align="center" valign="middle">IPI00179700</entry><entry valign="middle">HMGA1 Isoform HMG-I of High mobility group protein HMGI/HMG-Y</entry></row><row><entry align="center" valign="middle">IPI00554761</entry><entry valign="middle">HMGN1 Non-histone chromosomal protein HMG-14</entry></row><row><entry align="center" valign="middle">IPI00007764 (+1)</entry><entry valign="middle">HN1 Isoform 1 of Hematological and neurological expressed 1 protein</entry></row><row><entry align="center" valign="middle">IPI00396378</entry><entry valign="middle">HNRNPA2B1 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1</entry></row><row><entry align="center" valign="middle">IPI00218493</entry><entry valign="middle">HPRT1 Hypoxanthine-guanine phosphoribosyltransferase</entry></row><row><entry align="center" valign="middle">IPI00375631</entry><entry valign="middle">ISG15 Interferon-induced 17 kDa protein precursor</entry></row><row><entry align="center" valign="middle">IPI00024660 (+2)</entry><entry valign="middle">KIAA0174 Isoform 1 of Uncharacterized protein KIAA0174</entry></row><row><entry align="center" valign="middle">IPI00219217</entry><entry valign="middle">LDHB L-lactate dehydrogenase B chain</entry></row><row><entry align="center" valign="middle">IPI00465431</entry><entry valign="middle">LGALS3 Galectin-3</entry></row><row><entry align="center" valign="middle">IPI00021405 (+4)</entry><entry valign="middle">LMNA Isoform A of Lamin-A/C</entry></row><row><entry align="center" valign="middle">IPI00106668 (+1)</entry><entry valign="middle">M6PRBP1 Isoform A of Mannose-6-phosphate receptor-binding protein 1</entry></row><row><entry align="center" valign="middle">IPI00017596</entry><entry valign="middle">MAPRE1 Microtubule-associated protein RP/EB family member 1</entry></row><!-- EPO <DP n="64"> --><row><entry align="center" valign="middle">IPI00604590 (+1)</entry><entry valign="middle">NME2 Nucleoside diphosphate kinase</entry></row><row><entry align="center" valign="middle">IPI00301579</entry><entry valign="middle">NPC2 Epididymal secretory protein E1 precursor</entry></row><row><entry align="center" valign="middle">IPI00219129 (+3)</entry><entry valign="middle">NQO2 Ribosyldihydronicotinamide dehydrogenase</entry></row><row><entry align="center" valign="middle">IPI00004392 (+4)</entry><entry valign="middle">NUDT1 Isoform p26 of 7,8-dihydro-8-oxoguanine triphosphatase</entry></row><row><entry align="center" valign="middle">IPI00013297</entry><entry valign="middle">PDAP1 28 kDa heat- and acid-stable phosphoprotein</entry></row><row><entry align="center" valign="middle">IPI00219446</entry><entry valign="middle">PEBP1 Phosphatidylethanolamine-binding protein 1</entry></row><row><entry align="center" valign="middle">IPI00216691</entry><entry valign="middle">PFN1 Profilin-1</entry></row><row><entry align="center" valign="middle">IPI00419585</entry><entry valign="middle">PPIA;LOC654188;LOC653214 Peptidyl-prolyl cis-trans isomerase A</entry></row><row><entry align="center" valign="middle">IPI00646304</entry><entry valign="middle">PPIB peptidylprolyl isomerase B precursor</entry></row><row><entry align="center" valign="middle">IPI00026519</entry><entry valign="middle">PPIF Peptidyl-prolyl cis-trans isomerase, mitochondrial precursor</entry></row><row><entry align="center" valign="middle">IPI00000874 (+1)</entry><entry valign="middle">PRDX1 Peroxiredoxin-1</entry></row><row><entry align="center" valign="middle">IPI00024919 (+1)</entry><entry valign="middle">PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial precursor</entry></row><row><entry align="center" valign="middle">IPI00220301</entry><entry valign="middle">PRDX6 Peroxiredoxin-6</entry></row><row><entry align="center" valign="middle">IPI00014439</entry><entry valign="middle">QDPR Dihydropteridine reductase</entry></row><row><entry align="center" valign="middle">IPI00020436 (+2)</entry><entry valign="middle">RAB11B Ras-related protein Rab-11B</entry></row><row><entry align="center" valign="middle">IPI00032830 (+1)</entry><entry valign="middle">REXO2 Isoform 1 of Oligoribonuclease, mitochondrial precursor (Fragment)</entry></row><row><entry align="center" valign="middle">IPI00414896 (+1)</entry><entry valign="middle">RNASET2 Isoform 1 of Ribonuclease T2 precursor</entry></row><row><entry align="center" valign="middle">IPI00335280 (+1)</entry><entry valign="middle">RPE Isoform 1 of Ribulose-phosphate 3-epimerase</entry></row><row><entry align="center" valign="middle">IPI00026513 (+1)</entry><entry valign="middle">RPIA Ribose-5-phosphate isomerase</entry></row><row><entry align="center" valign="middle">IPI00179330</entry><entry valign="middle">RPS27A;UBC;UBB ubiquitin and ribosomal protein S27a precursor</entry></row><row><entry align="center" valign="middle">IPI00013895</entry><entry valign="middle">S100A11 Protein S100-A11</entry></row><row><entry align="center" valign="middle">IPI00027463</entry><entry valign="middle">S100A6 Protein S100-A6</entry></row><row><entry align="center" valign="middle">IPI00219806</entry><entry valign="middle">S100A7 Protein S100-A7</entry></row><row><entry align="center" valign="middle">IPI00007047</entry><entry valign="middle">S100A8 Protein S100-A8</entry></row><row><entry align="center" valign="middle">IPI00006252 (+1)</entry><entry valign="middle">SCYE1 Multisynthetase complex auxiliary component p43</entry></row><row><entry align="center" valign="middle">IPI00438170 (+2)</entry><entry valign="middle">SNX12 Isoform 1 of Sorting nexin-12</entry></row><row><entry align="center" valign="middle">IPI00289876 (+1)</entry><entry valign="middle">STX7 Isoform 1 of Syntaxin-7</entry></row><row><entry align="center" valign="middle">IPI00221222</entry><entry valign="middle">SUB1 Activated RNA polymerase II transcriptional coactivator p15</entry></row><!-- EPO <DP n="65"> --><row><entry align="center" valign="middle">IPI00550363</entry><entry valign="middle">TAGLN2 Transgelin-2</entry></row><row><entry align="center" valign="middle">IPI00465028</entry><entry valign="middle">TPI1 Isoform 1 of Triosephosphate isomerase</entry></row><row><entry align="center" valign="middle">IPI00072523 (+1)</entry><entry valign="middle">TPK1 Thiamin pyrophosphokinase 1</entry></row><row><entry align="center" valign="middle">IPI00550900</entry><entry valign="middle">TPT1 Translationally-controlled tumor protein</entry></row><row><entry align="center" valign="middle">IPI00022463 (+2)</entry><entry valign="middle">TRFE Human Serotransferrin precursor (Transferrin) (Siderophilin)</entry></row><row><entry align="center" valign="middle">IPI00815767</entry><entry valign="middle">TWF1 Isoform 3 of Twinfilin-1</entry></row><row><entry align="center" valign="middle">IPI00026328</entry><entry valign="middle">TXNDC12 Thioredoxin domain-containing protein 12 precursor</entry></row><row><entry align="center" valign="middle">IPI00179330</entry><entry valign="middle">UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor</entry></row><row><entry align="center" valign="middle">IPI00032957 (+2)</entry><entry valign="middle">UBE2I SUMO-conjugating enzyme UBC9</entry></row><row><entry align="center" valign="middle">IPI00021347</entry><entry valign="middle">UBE2L3 Ubiquitin-conjugating enzyme E2 L3</entry></row><row><entry align="center" valign="middle">IPI00018352</entry><entry valign="middle">UCHL1 Ubiquitin carboxyl-terminal hydrolase isozyme L1</entry></row><row><entry align="center" valign="middle">IPI00170692 (+1)</entry><entry valign="middle">VAPA Vesicle-associated membrane protein-associated protein A</entry></row><row><entry align="center" valign="middle">IPI00759832</entry><entry valign="middle">YWHAB Isoform Short of 14-3-3 protein beta/alpha</entry></row><row><entry align="center" valign="middle">IPI00000816</entry><entry valign="middle">YWHAE 14-3-3 protein epsilon</entry></row><row><entry align="center" valign="middle">IPI00021263</entry><entry valign="middle">YWHAZ 14-3-3 protein zeta/delta</entry></row></tbody></tgroup></table></tables></p><p id="p0116" num="0116">While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.</p></description><claims mxw-id="PCLM56977483" lang="EN" load-source="patent-office"><!-- EPO <DP n="66"> --><claim id="c-en-0001" num="0001"><claim-text>A chemorepellant for use in inducing negative chemotaxis of a human neutrophil, wherein the chemorepellant is an isolated apolipoprotein A1 or a biologically active fragment thereof, and wherein the isolated apolipoprotein A1 or biologically active fragment thereof induces chemorepulsion of the neutrophil.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>A chemorepellant for use in a method of inhibiting the chemotactic induction of a neutrophil in a patient in need thereof, wherein the chemorepellant is an isolated apolipoprotein Al or a biologically active fragment thereof, and wherein the isolated apolipoprotein Al or biologically active fragment thereof induces chemorepulsion of the neutrophil.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>A chemorepellant for use of claim 1 or claim 2, wherein the chemorepellant is isolated apolipoprotein A1.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>A chemorepellant for use of any one of claims 1 to 3, wherein the patient is suffering from an inflammatory condition.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>A chemorepellant for use in claim 4, wherein the inflammatory condition is selected from the group consisting of peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, acute or ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, inflammatory bowel disease (including, for example, Crohn's disease and ulcerative colitis), enteritis, Whipple's disease, asthma, chronic obstructive pulmonary disease, acute lung injury, ileus (including, for example, post-operative ileus), allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, cystic fibrosis, pneumonitis, pneumoultramicroscopic silicovolcanoconiosis, alvealitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, influenza, respiratory syncytial virus, herpes, disseminated bacteremia, Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cysts, bums, dermatitis, dermatomyositis, urticaria, acne, vasulitis, angiitis, endocarditis, arteritis,<!-- EPO <DP n="67"> --> atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, Alzheimer's disease, celiac disease, congestive heart failure, adult respiratory distress syndrome, meningitis, encephalitis, multiple sclerosis, cerebral infarction, cerebral embolism, Guillan- Barre syndrome, neuritis, neuralgia, uveitis, arthritides, arthralgias, osteomyelitis, fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thryoiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcet's syndrome, allograft rejection, graft-versus-host disease, Type I diabetes, ankylosing spondylitis, Berger's disease, Type II diabetes, Retier's syndrome, Hodgkins disease and injection site reaction.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>A chemorepellant for use in claim 5, wherein the inflammatory condition is injection site reaction.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>A chemorepellant for use of any one of claims 1 to 3, wherein chemotaxis toward a medical implant or graft is inhibited.</claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>A chemorepellant for use of any one of claims 1 to 7, wherein the chemorepellant is administered locally.</claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>An agent which inhibits activity of a chemorepellant released from a cancer cell for use in inducing migration of a neutrophil toward a cancer cell, wherein the chemorepellant is apolipoprotein A1.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>An agent for use of claim 9, wherein the activity of the apolipoprotein A1 is inhibited by the administration of an antibody that binds and inhibits the activity of the apolipoprotien A1, by an antisense nucleic acid or by a small molecule.</claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>An agent which inhibits the activity of a chemorepellant released from a cancer cell for use in a method for the treatment of cancer comprising inducing the migration of a neutrophil toward a cancer cell, wherein the chemorepellant is apolipoprotein A1.<!-- EPO <DP n="68"> --></claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>An agent for use of claim 11, wherein the cancer is selected from the group consisting of colon, prostate, breast, lung, skin, liver, bone, pancreas, ovary, testis, bladder, kidney, brain, head and neck cancer.</claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>An agent for use of claim 11, wherein the cancer is ovarian cancer.</claim-text></claim></claims><drawings mxw-id="PDW16668176" load-source="patent-office"><!-- EPO <DP n="69"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="135" he="183" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="70"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="141" he="190" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="71"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="145" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="72"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="151" he="219" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="73"> --><figure id="f0005" num="5"><img id="if0005" file="imgf0005.tif" wi="146" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="74"> --><figure id="f0006" num="6"><img id="if0006" file="imgf0006.tif" wi="161" he="226" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="75"> --><figure id="f0007" num="7"><img id="if0007" file="imgf0007.tif" wi="135" he="226" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="76"> --><figure id="f0008" num="8"><img id="if0008" file="imgf0008.tif" wi="141" he="230" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="77"> --><figure id="f0009" num="9"><img id="if0009" file="imgf0009.tif" wi="146" he="230" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="78"> --><figure id="f0010" num="10"><img id="if0010" file="imgf0010.tif" wi="141" he="230" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="79"> --><figure id="f0011" num="11"><img id="if0011" file="imgf0011.tif" wi="142" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="80"> --><figure id="f0012" num="12"><img id="if0012" file="imgf0012.tif" wi="141" he="231" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="81"> --><figure id="f0013" num="13"><img id="if0013" file="imgf0013.tif" wi="144" he="231" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="82"> --><figure id="f0014" num="14"><img id="if0014" file="imgf0014.tif" wi="145" he="230" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="83"> --><figure id="f0015" num="15"><img id="if0015" file="imgf0015.tif" wi="141" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="84"> --><figure id="f0016" num="16"><img id="if0016" file="imgf0016.tif" wi="136" he="229" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="85"> --><figure id="f0017" num="17"><img id="if0017" file="imgf0017.tif" wi="135" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="86"> --><figure id="f0018" num="18"><img id="if0018" file="imgf0018.tif" wi="137" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="87"> --><figure id="f0019" num="19"><img id="if0019" file="imgf0019.tif" wi="142" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="88"> --><figure id="f0020" num="20"><img id="if0020" file="imgf0020.tif" wi="137" he="229" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="89"> --><figure id="f0021" num="21A,21B"><img id="if0021" file="imgf0021.tif" wi="139" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="90"> --><figure id="f0022" num="22"><img id="if0022" file="imgf0022.tif" wi="144" he="220" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="91"> --><figure id="f0023" num="23A,23B"><img id="if0023" file="imgf0023.tif" wi="134" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="92"> --><figure id="f0024" num="24"><img id="if0024" file="imgf0024.tif" wi="163" he="173" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="93"> --><figure id="f0025" num="25"><img id="if0025" file="imgf0025.tif" wi="135" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="94"> --><figure id="f0026" num="26A,26B"><img id="if0026" file="imgf0026.tif" wi="165" he="186" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="95"> --><figure id="f0027" num="27"><img id="if0027" file="imgf0027.tif" wi="165" he="111" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="96"> --><figure id="f0028" num="28"><img id="if0028" file="imgf0028.tif" wi="146" he="230" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="97"> --><figure id="f0029" num="29A,29B"><img id="if0029" file="imgf0029.tif" wi="160" he="219" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="98"> --><figure id="f0030" num="30"><img id="if0030" file="imgf0030.tif" wi="155" he="135" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="99"> --><figure id="f0031" num="31"><img id="if0031" file="imgf0031.tif" wi="135" he="224" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="100"> --><figure id="f0032" num="32A,32B"><img id="if0032" file="imgf0032.tif" wi="165" he="194" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="101"> --><figure id="f0033" num="33"><img id="if0033" file="imgf0033.tif" wi="141" he="224" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="102"> --><figure id="f0034" num="34"><img id="if0034" file="imgf0034.tif" wi="140" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="103"> --><figure id="f0035" num="35"><img id="if0035" file="imgf0035.tif" wi="150" he="231" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="104"> --><figure id="f0036" num="36"><img id="if0036" file="imgf0036.tif" wi="146" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="105"> --><figure id="f0037" num="37"><img id="if0037" file="imgf0037.tif" wi="146" he="222" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="106"> --><figure id="f0038" num="38"><img id="if0038" file="imgf0038.tif" wi="142" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="107"> --><figure id="f0039" num="39"><img id="if0039" file="imgf0039.tif" wi="146" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="108"> --><figure id="f0040" num="40"><img id="if0040" file="imgf0040.tif" wi="158" he="98" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="159" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="158" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
